WO2023215850A2

WO2023215850A2 - Compositions and methods for the treatment of actinomycetia infections

Info

Publication number: WO2023215850A2
Application number: PCT/US2023/066638
Authority: WO
Inventors: Jason Holder; Helen Bartlett; Cody GLICKMAN; Sonia BARRIOS; Keith Solomon; Clinton C. DAWSON
Original assignee: Endolytix Technology, Inc.
Priority date: 2022-05-06
Filing date: 2023-05-05
Publication date: 2023-11-09
Also published as: WO2023215850A8; WO2023215850A3

Abstract

The present disclosure features compositions and methods for the treatment of actinomycetia (e.g., corynebacteriales) infections, e.g., caused by mycobacterial cells. In one aspect, the disclosure features a composition containing unencapsulated proteins that include one or more of (a) a Lysin A; (b) a Lysin B; (c) an isoamylase; and (d) an α-amylase. The composition optionally further includes a supramolecular structure including one or more (a) a Lysin A; (b) a Lysin B; (c) an isoamylase; and (d) an α-amylase. In another aspect, the invention features a method of treating a bacterial infection in a subject by administering a composition of unencapsulated lytic proteins as described herein to the subject in an amount and for a duration sufficient to treat the bacterial infection, optionally in combination with encapsulated lytic proteins. The encapsulated lytic proteins and the unencapsulated lytic proteins can be in the same or different composition and can be administered simultaneously or sequentially.

Description

COMPOSITIONS AND METHODS FOR THE TREATMENT OF ACTINOMYCETIA INFECTIONS

Sequence Listing

The instant application contains a Sequence Listing which has been submitted electronically in XML format and is hereby incorporated by reference in its entirety. Said XML copy, created on April 13, 2023, is named 51486-007WO4_Sequence_Listing_4_13_23.xml and is 660,323 bytes in size.

Background

Bacterial pathogens are a leading cause of infectious disease. Many bacteria are successfully detected by the human immune system and are rapidly cleared before onset of infection. However, some bacterial pathogens evade the host immune system by residing within a host cell. These intracellular bacteria have evolved diverse immune evasion techniques by residing and multiplying within host cells, such as immune cells (e.g., macrophages or dendritic cells), and the correct intracellular compartment (e.g., endosome, phagosome, lysosome, or cytosol) within the host cells. Bacterial infections that propagate within a host cell often present a difficult treatment barrier due to lack of accessibility of the subcellular location of the infection. While certain anti-bacterial compositions may treat the infection (e.g., in vitro), delivering the treatment to the correct subcellular location in which the bacteria reside has proved to be a challenging endeavor.

One group of challenging intracellular bacterial infections is caused by mycobacteria. Mycobacteria are actinomycetia (e.g., corynebacteriales or propionibacteriales), which are denoted by a thick envelope that is rich in mycolic acids. Mycobacteria contain an envelope that contains a cell membrane composed of a lipid, a cell wall that is comprised of peptidoglycan, arabinogalactan layer, and an outer membrane that is known as the mycomembrane, which is rich in mycolic acids. Many mycobacterial envelopes also contain an outer capsule layer composed of polysaccharides, such as D-glucan, D-arabino-D-mannan, and D-mannan. This complex cell envelope contributes to the hardiness of the mycobacteria and is particularly difficult to penetrate and destroy the mycobacterial cells.

These bacteria also contain a complex life cycle in which the bacteria reside in the cytoplasm or within other subcellular compartments or outside of a host cell. Mycobacteria are endocytosed by host cells, and these endocytosed vesicles can merge with intracellular organelles, such as endosomes, phagosomes, or lysosomes. Once inside these intracellular compartments, the bacteria can replicate and grow. This is followed by membrane solubilization and release of the bacteria into the cytoplasm, where they continue to grow. Subsequently, the bacteria lyse the host cell and spread as a free form of the bacteria. Such free-form bacteria may appear in the spleen and liver after release, e.g., from lung phagocytic cells, leading to expanded infection resulting in death.

Due to the complex life cycle, it is difficult to spatiotemporally target the bacteria at the appropriate locus to effectively treat the infection. For example, one must target the correct intracellular compartment at the correct life cycle stage when inside the host cell or target an extracellular location after host cell lysis. Accordingly, improved compositions and methods for targeting and treating bacterial infections, such as those caused by mycobacteria, are needed. Furthermore, a patient may have mycobacterial in various states of the lifecycle simultaneously.

Summary of the Invention

In one aspect, the invention features a composition containing unencapsulated proteins that includes one or more of (e.g., two or more, three or more, or all four of) (a) a Lysin A; (b) a Lysin B; (c) an isoamylase; and (d) an a-amylase.

In some embodiments, the composition includes Lysin A and Lysin B.

In some embodiments, the composition includes Lysin A and isoamylase.

In some embodiments, the composition includes Lysin A and a-amylase.

In some embodiments, the composition includes Lysin B and isoamylase.

In some embodiments, the composition includes Lysin B and a-amylase.

In some embodiments, the composition includes isoamylase and a-amylase.

In some embodiments, the composition includes Lysin A, Lysin B, and isoamylase.

In some embodiments, the composition includes Lysin A, Lysin B, and a-amylase.

In some embodiments, the composition includes Lysin A, isoamylase, and a-amylase.

In some embodiments, the composition includes Lysin B, isoamylase, and a-amylase

In some embodiments, the composition includes Lysin A, Lysin B, isoamylase, and a- amylase.

In some embodiments, the invention features a composition containing unencapsulated proteins that includes one or more of (e.g., two or more, three or more, or all four of) (a) a Lysin A that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 1-182; (b) a Lysin B that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241 ; (c) an isoamylase that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392; and (d) an a-amylase including an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the invention features a composition containing unencapsulated proteins that includes one or more of (e.g., two or more, three or more, or all four of) (a) a Lysin A that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; (b) a Lysin B that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; (c) an isoamylase that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and (d) an a-amylase including an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398.

In some embodiments, the composition includes Lysin A and Lysin B, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 1-182; and the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241.

In some embodiments, the composition includes Lysin A and Lysin B, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; and the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184.

In some embodiments, the composition includes Lysin A and isoamylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 1-182; and the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392.

In some embodiments, the composition includes Lysin A and isoamylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; and the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243.

In some embodiments, the composition includes Lysin A and a-amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 1-182; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the composition includes Lysin A and a-amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398.

In some embodiments, the composition includes Lysin B and isoamylase, and the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241 ; and the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392.

In some embodiments, the composition includes Lysin B and isoamylase, and the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; and the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243.

In some embodiments, the composition includes Lysin B and a-amylase, and the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241 ; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the composition includes Lysin B and a-amylase, and the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398.

In some embodiments, the composition includes isoamylase and a-amylase, and the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the composition includes isoamylase and a-amylase, and the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398.

In some embodiments, the composition includes Lysin A, Lysin B, and isoamylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 1-182; the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241 ; and the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392.

In some embodiments, the composition includes Lysin A, Lysin B, and isoamylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; and the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243.

In some embodiments, the composition includes Lysin A, Lysin B, and a-amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 1-182; the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241 ; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the composition includes Lysin A, Lysin B, and a-amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398.

In some embodiments, the composition includes Lysin A, isoamylase, and a-amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 1-182; the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the composition includes Lysin A, isoamylase, and a-amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398.

In some embodiments, the composition includes Lysin B, isoamylase, and a-amylase, and the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241 ; the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the composition includes Lysin B, isoamylase, and a-amylase, and the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398.

In some embodiments, the composition includes Lysin A, Lysin B, isoamylase, and a- amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 1-182; the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241 ; the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the composition includes Lysin A, Lysin B, isoamylase, and a- amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398.

In some embodiments, the composition includes Lysin A, Lysin B, isoamylase, and a- amylase, and the Lysin A includes the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2; the Lysin B includes the amino acid sequence of SEQ ID NO: 183 or SEQ ID NO: 184; the isoamylase includes the amino acid sequence of SEQ ID NO: 242 or SEQ ID NO: 243; and the a-amylase includes the amino acid sequence of any one of SEQ ID NOs: 393-398.

In some embodiments, the composition includes a Lysin A of SEQ ID NO: 1 , a Lysin B of SEQ ID NO: 183, an isoamylase of SEQ ID NO: 242, and an a-amylase of SEQ ID NO: 393. In some embodiments, the composition includes a Lysin A of SEQ ID NO: 2, a Lysin B of SEQ ID NO: 184, an isoamylase of SEQ ID NO: 243, and an a-amylase of SEQ ID NO: 394.

In some embodiments, the composition includes a Lysin A of SEQ ID NO: 1 , a Lysin B of SEQ ID NO: 183, an isoamylase of SEQ ID NO: 242, and an a-amylase of SEQ ID NO: 395. In some embodiments, the composition includes a Lysin A of SEQ ID NO: 2, a Lysin B of SEQ ID NO: 184, an isoamylase of SEQ ID NO: 243, and an a-amylase of SEQ ID NO: 396.

In some embodiments, the composition includes a Lysin A of SEQ ID NO: 1 , a Lysin B of SEQ ID NO: 183, an isoamylase of SEQ ID NO: 242, and an a-amylase of SEQ ID NO: 397. In some embodiments, the composition includes a Lysin A of SEQ ID NO: 2, a Lysin B of SEQ ID NO: 184, an isoamylase of SEQ ID NO: 243, and an a-amylase of SEQ ID NO: 398.

In some embodiments, the composition includes a concentration of proteins (e.g., Lysin A, Lysin B, isoamylase, and/or a-amylase) of from 0.1 mg/mL to 20 mg/mL (e.g., e.g., from 0.1 mg/mL to

I mg/mL, e.g., 0.1 mg/mL, 0.2 mg/mL, 0.3 mg/mL, 0.4 mg/mL, 0.5 mg/mL, 0.6 mg/mL, 0.7 mg/mL, 0.8 mg/mL, 0.9 mg/mL, or 1 mg/mL, e.g., from 1 mg/mL to 10 mg/mL, e.g., 2 mg/mL, 3 mg/mL, 4 mg/mL, 5 mg/mL, 6 mg/mL, 7 mg/mL, 8 mg/mL, 9 mg/mL, 10 mg/mL, e.g., from 10 mg/mL to 20 mg/mL, e.g.,

I I mg/mL, 12 mg/mL, 13 mg/mL, 14 mg/mL, 15 mg/mL, 16 mg/mL, 17 mg/mL, 18 mg/mL, 19 mg/mL, or 20 mg/mL). In some embodiments, the composition includes a concentration of Lysin A, Lysin B, isoamylase, and/or a-amylase of from 1 mg/mL to 10 mg/mL.

In some embodiments, the composition further includes a supramolecular structure including one or more (e.g., two or more, three or more, or all four of) (a) a Lysin A; (b) a Lysin B; (c) an isoamylase; and (d) an a-amylase.

In some embodiments, the composition includes Lysin A and Lysin B.

In some embodiments, the composition includes Lysin A and isoamylase. In some embodiments, the composition includes Lysin A and a-amylase.

In some embodiments, the composition includes Lysin B and isoamylase.

In some embodiments, the composition includes Lysin B and a-amylase.

In some embodiments, the composition includes isoamylase and a-amylase.

In some embodiments, the composition includes Lysin A, Lysin B, and isoamylase.

In some embodiments, the composition includes Lysin A, Lysin B, and a-amylase.

In some embodiments, the composition further includes a supramolecular structure including one or more (e.g., two or more, three or more, or all four of) (a) a Lysin A that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 1-182; (b) a Lysin B that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241 ; (c) an isoamylase that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392; and (d) an a-amylase including an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the composition further includes a supramolecular structure including one or more (e.g., two or more, three or more, or all four of) (a) a Lysin A that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; (b) a Lysin B that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; (c) an isoamylase that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and (d) an a-amylase including an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398.

In some embodiments, the supramolecular structure includes Lysin A and Lysin B, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 1-182; and the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241.

In some embodiments, the supramolecular structure includes Lysin A and Lysin B, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; and the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184.

In some embodiments, the supramolecular structure includes Lysin A and isoamylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 1-182; and the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392.

In some embodiments, the supramolecular structure includes Lysin A and isoamylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; and the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243.

In some embodiments, the supramolecular structure includes Lysin A and a-amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 1 -182; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the supramolecular structure includes Lysin A and a-amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398.

In some embodiments, the supramolecular structure includes Lysin B and isoamylase, and the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241 ; and the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392.

In some embodiments, the supramolecular structure includes Lysin B and isoamylase, and the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; and the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243.

In some embodiments, the supramolecular structure includes Lysin B and a-amylase, and the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241 ; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the supramolecular structure includes Lysin B and a-amylase, and the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398.

In some embodiments, the supramolecular structure includes isoamylase and a-amylase, and the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the supramolecular structure includes isoamylase and a-amylase, and the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398.

In some embodiments, the supramolecular structure includes Lysin A, Lysin B, and isoamylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 1-182; the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241 ; and the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392.

In some embodiments, the supramolecular structure includes Lysin A, Lysin B, and isoamylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; and the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243.

In some embodiments, the supramolecular structure includes Lysin A, Lysin B, and a- amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 1-182; the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241 ; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the supramolecular structure includes Lysin A, Lysin B, and a- amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398.

In some embodiments, the supramolecular structure includes Lysin A, isoamylase, and a- amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 1-182; the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the supramolecular structure includes Lysin A, isoamylase, and a- amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398.

In some embodiments, the supramolecular structure includes Lysin B, isoamylase, and a- amylase, and the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241 ; the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the supramolecular structure includes Lysin B, isoamylase, and a- amylase, and the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398.

In some embodiments, the supramolecular structure includes Lysin A, Lysin B, isoamylase, and a-amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 1-182; the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241 ; the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the supramolecular structure includes Lysin A, Lysin B, isoamylase, and a- amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398. In some embodiments, the supramolecular structure includes Lysin A, Lysin B, isoamylase, and a- amylase, and the Lysin A includes the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2; the Lysin B includes the amino acid sequence of SEQ ID NO: 183 or SEQ ID NO: 184; the isoamylase includes the amino acid sequence of SEQ ID NO: 242 or SEQ ID NO: 243; and the a-amylase includes the amino acid sequence of any one of SEQ ID NOs: 393-398.

In some embodiments, the supramolecular structure includes a Lysin A of SEQ ID NO: 1 , a Lysin B of SEQ ID NO: 183, an isoamylase of SEQ ID NO: 242, and an a-amylase of SEQ ID NO: 393. In some supramolecular structure, the composition includes a Lysin A of SEQ ID NO: 2, a Lysin B of SEQ ID NO: 184, an isoamylase of SEQ ID NO: 243, and an a-amylase of SEQ ID NO: 394.

In some embodiments, the supramolecular structure includes a Lysin A of SEQ ID NO: 1 , a Lysin B of SEQ ID NO: 183, an isoamylase of SEQ ID NO: 242, and an a-amylase of SEQ ID NO:

395. In some embodiments, the supramolecular structure includes a Lysin A of SEQ ID NO: 2, a Lysin B of SEQ ID NO: 184, an isoamylase of SEQ ID NO: 243, and an a-amylase of SEQ ID NO:

396.

397. In some embodiments, the supramolecular structure includes a Lysin A of SEQ ID NO: 2, a Lysin B of SEQ ID NO: 184, an isoamylase of SEQ ID NO: 243, and an a-amylase of SEQ ID NO:

398.

In some embodiments, the Z-average mean particle diameter of the supramolecular structure is from 75 nm to 5 pm, e.g., from 75 nm to 2 pm, from 75 nm to 1 pm, e.g., from 75 nm to 750 nm (e.g., from 250 nm to 750 nm, or from 75 nm to 250 nm). In some embodiments, when the supramolecular structure is an LNP or micelle, the Z-average mean particle diameter is from 75 nm to 250 nm. In some embodiments, when the supramolecular structure is a vesicle (e.g., a liposome), the Z-average mean particle diameter is from 250 nm to 750 nm. Non-limiting examples of the Z-average mean particle diameters include, e.g., from 75 nm to 100 nm, e.g., from 75 nm to 85 nm, e.g., 80 nm, e.g., from 80 nm to 140 nm, from 90 nm to 130 nm, or from 110 nm to 130 nm, e.g., 120 nm, e.g., from 200 nm to 300 nm, e.g., from 250 nm to 300 nm, from 260 nm to 290 nm, from 260 nm to 280 nm, from 265 nm to 275 nm, e.g., 270 nm, e.g., from 300 nm to 400 nm, from 400 nm to 600 nm, e.g., from 450 nm to 550 nm, from 475 nm to 525 nm, from 480 nm to 520 nm, from 490 nm to 510 nm, from 495 nm to 505 nm, e.g., 500 nm, e.g., 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, 150 nm, 155 nm, 160 nm, 165 nm, 170 nm, 175 nm, 180 nm, 185 nm, 190 nm, 195 nm, 200 nm, 205 nm, 210 nm, 215 nm, 220 nm, 225 nm, 230 nm, 235 nm, 240 nm, 245 nm, 250 nm, 255 nm, 260 nm, 265 nm, 270 nm, 275 nm, 280 nm, 285 nm, 290 nm, 295 nm, 300 nm, 305 nm, 310 nm, 315 nm, 320 nm, 325 nm, 330 nm, 335 nm, 340 nm, 345 nm, 350 nm, 355 nm, 360 nm, 365 nm, 370 nm, 375 nm, 380 nm, 385 nm, 390 nm, 395 nm, 400 nm, 405 nm, 410 nm, 415 nm, 420 nm, 425 nm, 430 nm, 435 nm, 440 nm, 445 nm, 450 nm, 455 nm, 460 nm, 465 nm, 470 nm, 475 nm, 480 nm, 485 nm, 490 nm, 495 nm, 500 nm, 505 nm, 510 nm, 515 nm, 520 nm, 525 nm, 530 nm, 535 nm, 540 nm, 545 nm, 550 nm, 555 nm, 560 nm, 565 nm, 570 nm, 575 nm, 580 nm, 585 nm, 590 nm, 595 nm, 600 nm, 605 nm, 610 nm, 615 nm, 620 nm, 625 nm, 630 nm, 635 nm, 640 nm, 645 nm, 650 nm, 655 nm, 660 nm, 665 nm, 670 nm, 675 nm, 680 nm,

685 nm, 690 nm, 695 nm, 700 nm, 705 nm, 710 nm, 715 nm, 720 nm, 725 nm, 730 nm, 735 nm, 740 nm, 745 nm, 750 nm, 755 nm, 760 nm, 765 nm, 770 nm, 775 nm, 780 nm, 785 nm, 790 nm, 795 nm,

800 nm, 805 nm, 810 nm, 815 nm, 820 nm, 825 nm, 830 nm, 835 nm, 840 nm, 845 nm, 850 nm, 855 nm, 860 nm, 865 nm, 870 nm, 875 nm, 880 nm, 885 nm, 890 nm, 895 nm, 900 nm, 905 nm, 910 nm,

915 nm, 920 nm, 925 nm, 930 nm, 935 nm, 940 nm, 945 nm, 950 nm, 955 nm, 960 nm, 965 nm, 970 nm, 975 nm, 980 nm, 985 nm, 990 nm, 995 nm, 1 pm, 1.1 pm, 1.2 pm, 1.3 pm, 1.4 pm, 1.5 pm, 1.6 pm, 1.7 pm, 1.8 pm, 1.9 pm, 2 pm, 2.1 pm, 2.2 pm 2.3 pm, 2.4 pm, 2.5 pm, 2.6 pm, 2.7 pm, 2.8 pm, 2.9 pm, 3 pm, 3.1 pm, 3.2 pm, 3.3 pm, 3.4 pm, 3.5 pm, 3.6 pm, 3.7 pm, 3.8 pm, 3.9 pm, 4 pm, 4.1 pm 4.2 pm 4.3 pm, 4.4 pm, 4.5 pm, 4.6 pm, 4.7 pm, 4.8 pm, 4.9 pm, or 5 pm. In some embodiments, the Z-average mean particle diameter of the supramolecular structure is 80 nm, 270 nm, or 500 nm. In some embodiments, the supramolecular structure includes a Z-average mean particle diameter of from 75 nm to 750 nm. In some embodiments, the Z-average mean particle diameter is from 250 nm to 750 nm. In some embodiments, the Z-average mean particle diameter is from 75 nm to 250 nm.

In some embodiments, the supramolecular structure is a is a lipid nanoparticle.

In some embodiments, the supramolecular structure is a micelle.

In some embodiments, the supramolecular structure is a liposome. The liposome may be unilamellar. Alternatively, the liposome may be multilamellar.

In some embodiments, the supramolecular structure includes polydispersity index of from 0.05 to 0.3.

In some embodiments, the supramolecular structure includes one or more lipids. In some embodiments, at least one of the one or more lipids may be, for example, an ionizable lipid. The lipid may be, for example, 1 ,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1 ,2-dioleoyl-sn- glycero-3-phosphoethanolamine (DOPE), or 1 ,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS).

In some embodiments, the lipid is a sterol, e.g., cholesterol or a derivative thereof.

In some embodiments, the supramolecular structure includes a mixture of lipids. For example, the mixture of lipids may include two or more of DOPC, DOPE, DOPS, and cholesterol. In some embodiments, the DOPC and DOPE are present at a molar ration of from 10:1 to 1 :10 (e.g., 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10).

In some embodiments, the DOPC and DOPS are present at a molar ratio of from 10:1 to 1 :10 (e.g., 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10).

In some embodiments, the DOPC and cholesterol are present at a molar ratio of from 10:1 to 1:10 (e.g., 10:1 , 9:1 , 8:1 , 7:1 , 6:1 , 5:1 , 4:1 , 3:1 , 2:1 , 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10).

In some embodiments, the DOPE and DOPS are present at a molar ratio of from 10:1 to 1 :10 (e.g., 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10).

In some embodiments, the DOPE and cholesterol are present at a molar ratio of from 10:1 to 1:10(e.g., 10:1,9:1,8:1,7:1,6:1,5:1,4:1,3:1,2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10).

In some embodiments, the DOPS and cholesterol are present at a molar ratio of from 10:1 to 1:10 (e.g., 10:1 , 9:1 , 8:1 , 7:1 , 6:1 , 5:1 , 4:1 , 3:1 , 2:1 , 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10). In some embodiments, the DOPC, DOPE, DOPS, and cholesterol are present at a molar ratio of from 1-20:1-20:1-5:1-5. For example, in some embodiments, the DOPC, DOPE, DOPS, and cholesterol are present at a molar ratio of 10:10:3:4.

In some embodiments, the supramolecular structure includes a concentration of lipids of from 0.1 mg/mL to 10 mg/mL (e.g., from 0.1 mg/mL to 1 mg/mL, e.g., 0.1 mg/mL, 0.2 mg/mL, 0.3 mg/mL, 0.4 mg/mL, 0.5 mg/mL, 0.6 mg/mL, 0.7 mg/mL, 0.8 mg/mL, 0.9 mg/mL, or 1 mg/mL, e.g., from 1 mg/mL to 10 mg/mL, e.g., 2 mg/mL, 3 mg/mL, 4 mg/mL, 5 mg/mL, 6 mg/mL, 7 mg/mL, 8 mg/mL, 9 mg/mL, or 10 mg/mL). In some embodiments, the supramolecular structure includes a concentration of lipids of from 1 mg/mL to 5 mg/mL.

In some embodiments, the supramolecular structure includes a concentration of proteins (e.g., Lysin A, Lysin B, isoamylase, and/or a-amylase) of from 0.1 mg/mL to 20 mg/mL (e.g., e.g., from 0.1 mg/mL to 1 mg/mL, e.g., 0.1 mg/mL, 0.2 mg/mL, 0.3 mg/mL, 0.4 mg/mL, 0.5 mg/mL, 0.6 mg/mL, 0.7 mg/mL, 0.8 mg/mL, 0.9 mg/mL, or 1 mg/mL, e.g., from 1 mg/mL to 10 mg/mL, e.g., 2 mg/mL, 3 mg/mL, 4 mg/mL, 5 mg/mL, 6 mg/mL, 7 mg/mL, 8 mg/mL, 9 mg/mL, 10 mg/mL, e.g., from 10 mg/mL to 20 mg/mL, e.g., 11 mg/mL, 12 mg/mL, 13 mg/mL, 14 mg/mL, 15 mg/mL, 16 mg/mL, 17 mg/mL, 18 mg/mL, 19 mg/mL, or 20 mg/mL). In some embodiments, the composition includes a concentration of Lysin A, Lysin B, isoamylase, and/or a-amylase of from 1 mg/mL to 10 mg/mL.

In some embodiments, the supramolecular structure described herein is formulated with one or more buffers and/or excipients. For example, the supramolecular structure, (e.g., a liposome containing a cocktail of lytic enzymes) may be encapsulated and/or formulated in buffer, such as glycine, Tris, sodium citrate, sodium acetate, and MES, e.g., at a concentration of 10 mM to 200 mM, e.g., 50 mm to 150 mm, e.g., 10 mM, 20 mm, 30 mm, 40 mm, 50 mm, 60 mm, 70 mm, 80 mm, 90 mM, 100 mM, 110 mM, 120 mM, 130 mM, 140 mM, 150 mM, 160 mM, 170 mM, 180 mM, 190 mM, or 200 mM. The supramolecular structure may be formulated at a pH of from 5 to 11 (e.g., a pH of 5 to 6, e.g., 5.1 , 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, or 6, e.g., 6 to 1 1 , e.g., 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, or 1 1). The supramolecular structure may further include one or more excipients, such as CaCh, arginine, NaCI, sodium citrate, MgCh, or glycerol. In some embodiments, the supramolecular structure includes, for example, 5 mM to 10 mM CaCh, 0 to 50 mM arginine, 0 to 200 mM NaCI, 0 to 1 mM sodium citrate, 0 to 1 mM MgCh, and/or 10-30% glycerol. In some embodiments, the supramolecular structure includes 50 mM glycine, pH 8.5, 7.5 mM CaCh, 0.5 mM MgCh, 200 mM NaCI, 0.33 mM sodium citrate, and 10% glycerol. The formulation may further include TWEEN, e.g., TWEEN-80.

In some embodiments, the supramolecular structure further includes a targeting moiety. The targeting moiety may be, for example an extracellular targeting moiety targeting a professional antigen presenting cell (e.g., a macrophage or a dendritic cell). In some embodiments, the targeting moiety is phosphatidylserine.

In another aspect, the invention features a method of treating a bacterial infection in a subject. The method includes administering a composition as described herein, e.g., of any of the above embodiments, to the subject in an amount and for a duration sufficient to treat the bacterial infection. In some embodiments, the method further includes administering a supramolecular structure including one or more (e.g., two or more, three or more, or all four of) (a) a Lysin A that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 1-182; (b) a Lysin B that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241 ; (c) an isoamylase that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392; and (d) an a-amylase including an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the method further includes administering a supramolecular structure including one or more (e.g., two or more, three or more, or all four of) (a) a Lysin A that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; (b) a Lysin B that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; (c) an isoamylase that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and (d) an a-amylase including an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398.

In some embodiments, the supramolecular structure includes Lysin A, isoamylase, and a- amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398. In some embodiments, the supramolecular structure includes Lysin B, isoamylase, and a- amylase, and the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 183-241 ; the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 242-392; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-445.

In some embodiments, the supramolecular structure includes Lysin A, Lysin B, isoamylase, and a-amylase, and the Lysin A includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; the Lysin B includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; the isoamylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and the a-amylase includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398.

In some embodiments, the supramolecular structure includes Lysin A, Lysin B, isoamylase, and a-amylase, and the Lysin A includes the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2; the Lysin B includes the amino acid sequence of SEQ ID NO: 183 or SEQ ID NO: 184; the isoamylase includes the amino acid sequence of SEQ ID NO: 242 or SEQ ID NO: 243; and the a- amylase includes the amino acid sequence of any one of SEQ ID NOs: 393-398.

396.

398.

In some embodiments, the composition is administered prior to the supramolecular structure.

In some embodiments, the composition is administered after the supramolecular structure.

In some embodiments, the composition is administered at substantially the same time as the supramolecular structure.

In some embodiments the bacterial infection is caused by an actinomycetia bacterium. In some embodiments, the actinomycetia is a corynebacteriales or propionibacteriales. In some embodiments, the cornyebacteriales is a Mycobacterium species.

In some embodiments, the Mycobacterium species is M. tuberculosis, M. leprae, M. lepromatosis, M. avium, M. kansasii, M. fortuitum, M. chelonae, M. marinum, M. intracellulare, M. abscessus, M. chimera, M. boletti, M. fortuitum, M. goodii, or M. masiliense.

In some embodiments, the corynebacteriales is a Nocardia, Corynebacterium, or Rhodococcus species.

In some embodiments, the propionibacteriales is a Cutibacterium species.

In some embodiments, the compositions and methods described herein may be used to target other actinomycetia (e.g., corynebacteriales or propionibacteriales) that have similar envelope components as mycobacteria. For example, the compositions and methods may be used to target a Nocardia, Corynebacterium, or Rhodococcus species. For example, the Nocardia species may be, e.g., N. brasiliensis, N. cyriacigeorgica, N. farcinica, N. nova, N. asteroids, N. brasiliensis, and N. caviae. The Corynebacterium species may be, e.g., C. glutamicum or C. diphtheriae. The Rhodococcus species may be, e.g., R. fascians or R. equi.

In some embodiments, the compositions and methods may be used to target a Cutibacterium species. The Cutibacterium species may be, e.g., C. acnes.

In some embodiments, the method further includes administering an antibiotic. In some embodiments, the antibiotic is a cephalosporin, a carbapenem, a penicillin, an aminoglycoside, a cephalosporin, a rifamycin, a macrolide, or a fluoroquinolone. In some embodiments, the antibiotic is thiacetazone, sq-109, bedaquiline, delamanid, pyrazinamide, or isoniazid. In some embodiments, the antibiotic is azithromycin, clarithromycin, ethambutol, rifampin, biapenem, or amikacin. In some embodiments, the antibiotic is a macrolide (e.g., azithromycin, clarithromycin, erythromycin). In some embodiments, the antibiotic is a macrolide (e.g., azithromycin, clarithromycin, erythromycin). In some embodiments, the antibiotic is an aminoglycoside (e.g., kanamycin A, amikacin, tobramycin, dibekacin, gentamicin, sisomicin, netilmicin, neomycin (e.g., neomycin B, C, or E), streptomycin, or plazomicin).

In some embodiments, the composition is administered intravenously, orally, or via inhalation (e.g., via aerosol).

In some embodiments, the compositions and methods described herein target bacteria that reside extracellularly for at least a portion of their life cycle.

In some embodiments, the compositions and methods described herein target bacteria that reside intracellularly for at least a portion of their life cycle.

In some embodiments, the compositions and methods described herein target bacteria that reside extracellularly and intracellularly for at least a portion of their life cycle.

Definitions

As used herein, the term “about” refers to +/- 10% of a recited value.

As used herein, a “combination therapy” or “administered in combination” means that two (or more) agents or treatments are administered to a subject as part of a defined treatment regimen for a particular disease or condition. The treatment regimen defines the doses and periodicity of administration of each agent such that the effects of the separate agents on the subject overlap and/or allow for synergism. In some embodiments, the delivery of the two or more agents is simultaneous or concurrent, and the agents may be co-formulated. In some embodiments, the two or more agents are not co-formulated and are administered in a sequential manner as part of a prescribed regimen. In some embodiments, administration of two or more agents or treatments in combination is such that the reduction in a symptom, or other parameter related to the disease, is greater than what would be observed with one agent or treatment delivered alone or in the absence of the other. The effect of the two treatments can be partially additive, wholly additive, or greater than additive, e.g., synergistic. Sequential or substantially simultaneous administration of each therapeutic agent can be by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, topical routes, and direct absorption through mucous membrane tissues. The therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination may be administered by intravenous injection while a second therapeutic agent of the combination may be administered orally.

As used herein, the terms “effective amount,” “therapeutically effective amount,” and “sufficient amount” of an agent that results in a therapeutic effect, e.g., in a cell, sample, or subject, described herein refer to a quantity sufficient to, when administered to the cell, sample, or subject, including a human, effect beneficial or desired results, including pre-clinical or clinical results, and, as such, an “effective amount” or synonym thereto depends on the context in which it is being applied. For example, in the context of treating a disorder, it is an amount of the agent that is sufficient to achieve a treatment response as compared to the response obtained without administration of the agent. The amount of a given agent will vary depending upon various factors, such as the given agent, the pharmaceutical formulation, the route of administration, the severity of the bacterial infection, biomarkers, e.g., age, sex, and/or weight, of the subject, sample, or host cell, e.g., mammalian immune cell, being treated, and the like, but can nevertheless be routinely determined by one of ordinary skill in the art. Also, as used herein, the term “therapeutically effective amount” of an agent is an amount which results in a beneficial or desired result in a cell or subject as compared to a control. As defined herein, a therapeutically effective amount of an agent may be readily determined by one of ordinary skill by routine methods known in the art. Dosage regimen may be adjusted to provide the optimum therapeutic response.

The term “antibacterial lytic protein,” as used herein, refers to a protein that has bactericidal and/or bacteriolytic activity against bacteria. Non-limiting examples of antibacterial lytic proteins include holins, lysins (e.g., Lysin A and/or Lysin B), amylases (e.g., isoamylase or a-amylase), capsule depolymerases (e.g., hydrolase, metallohydrolase, epoxide hydrolase, peptidoglycan hydrolase, polysaccharase, polysaccharide lyase, endosialidase, hyaluronan lyase, or alginate lyase), beta lactamases, and lysozyme.

As used herein, "lipid nanoparticle" or"LNP" is a vesicle that includes a lipid layer encapsulating a substantially solid lipid core; the lipid core can contain a pharmaceutically active molecule. LNPs typically contain a cationic lipid, a non-cationic lipid, and a lipid that prevents aggregation of the particle (e.g., a PEG-lipid conjugate).

As used herein, the term "liposome" refers to a vesicle composed of amphiphilic lipids arranged in at least one bilayer, e.g., one bilayer or a plurality of bilayers. Liposomes include unilamellar and multilamellar (e.g., 2, 3, 4, 5, or more lamella) vesicles that have a membrane formed from a lipophilic material and an aqueous interior. The aqueous portion contains an antibacterial lytic protein or mixture of an antibacterial lytic protein and other components. The lipophilic material isolates the aqueous interior from an aqueous exterior, which typically does not include the phage protein, although in some examples, it may. Liposomes also include "sterically stabilized" liposomes, a term which, as used herein, refers to liposomes that include one or more specialized lipids that, when incorporated into liposomes, result in enhanced circulation lifetimes relative to liposomes lacking such specialized lipids.

"Micelles" are defined herein as a particular type of substantially spherical supramolecular structure in which amphiphilic molecules, e.g., lipids, are arranged such that the hydrophobic portions of the molecules are directed inward toward the core, leaving the hydrophilic portions in contact with the surrounding aqueous phase. The converse arrangement exists if the surrounding environment is hydrophobic. The micelle core may contain the antibacterial lytic protein or mixture of proteins.

As used herein, the term “subject” refers to any organism to which a composition in accordance with the invention may be administered, e.g., for experimental, diagnostic, prophylactic, and/or therapeutic purposes. Typical subjects include any animal, e.g., mammals such as mice, rats, rabbits, non-human primates, and humans. A subject may seek or be in need of treatment, require treatment, be receiving treatment, be receiving treatment in the future, or be a human or animal who is under care by a trained professional for a particular disease or condition. As used herein, the term “supramolecular structure” refers to a complex of molecules held together by noncovalent bonds, such as hydrogen bonds, Van der Waals forces, electrostatic interactions, hydrophobic effect, and Pi-Pi interactions. Supramolecular structures may include large complexes of molecules that form, e.g., sphere-like structures. Supramolecular structures include, for example, lipid-based supramolecular structures, such as liposomes, lipid nanoparticles, and micelles.

As used herein, the term “targeted intracellular compartment” refers to an endosome, phagosome, lysosome, or cytosol.

As used herein, the term “unencapsulated proteins” refers to free proteins that are not present in a supramolecular structure. For example, unencapsulated proteins are not formulated within a liposome, a lipid nanoparticle, or a micelle.

The term “targeting moiety,” as used herein, represents a moiety (e.g., a small molecule, e.g., a carbohydrate) that specifically binds or reactively associates or complexes with a receptor or other receptive moiety associated with a given target cell population (e.g., a professional antigen-presenting cell, e.g., macrophage or dendritic cell). Thus, a targeting moiety may be used to target a supramolecular structure described herein to, e.g., a professional antigen-presenting cell (e.g., macrophage or dendritic cell).

"Vesicles" are defined herein as a type of a supramolecular structure in which amphipathic molecules (e.g., lipids) collectively define a volume, e.g., a substantially spherical volume. Amphipathic molecules (e.g., lipids) typically make up at least one shell of a vesicle. In this shell, the amphipathic molecules are arranged in a bilayer with hydrophilic portions of the amphipathic molecules being outwardly directed relative to the plane of the bilayer and the hydrophobic portions of the amphipathic molecules being disposed predominantly within the bilayer. The converse arrangement exists if the surrounding medium is hydrophobic.

Brief Description of the Drawings

FIG. 1 is a graph showing serial dilutions of M. abscessus infected macrophages that were treated with either free Lysin A, Lysin B, isoamylase, and a-amylase (ABIa) or liposomes containing ABIa.

Detailed Description

Mycobacteria are actinomycetia (e.g., corynebacteriales or propionibacteriales) that are denoted by a thick envelope that is rich in mycolic acids. Mycobacteria contain, from outside to inside, a capsule, mycolic acid layer, arabinogalactan (AGL) layer, peptidoglycan (PG), plasma membrane, and cytoplasm. This complex cell envelope contributes to the hardiness of the mycobacteria and is particularly difficult to penetrate and destroy, which is needed for the effective treatment of mycobacterial infections.

Furthermore, these bacteria also contain a complex life cycle in which the bacteria reside in the cytoplasm or within other subcellular compartments of a host cell or outside the host cell. Mycobacteria are endocytosed by host cells, and these endocytosed vesicles can merge with intracellular organelles, such as endosomes, phagosomes, or lysosomes. Once inside these intracellular compartments, the bacteria can replicate and grow. This is followed by membrane solubilization and release of the bacteria into the cytoplasm, where they continue to grow. Subsequently, the bacteria lyse the host cell and spread as a free form of the bacteria. Such freeform bacteria may appear in the spleen and liver after release, e.g., from lung phagocytic cells, leading to expanded infection resulting in death.

Due to the complex life cycle, it is difficult to spatiotemporally target the bacteria at the appropriate locus to effectively treat the infection. For example, one must target the correct intracellular compartment at the correct life cycle stage when inside the host cell or target an extracellular location after host cell lysis. Accordingly, improved compositions and methods for targeting and treating bacterial infections, such as those caused by mycobacteria, are needed.

The present invention solves this problem with a composition of matter and methods of use thereof that was rationally designed to degrade the mycobacterial envelope and specifically target both the free form intraphagosomal phase and the intracellular life cycle phase of the mycobacterial life cycle. The composition includes a cocktail of unencapsulated antibacterial lytic proteins that are primed to kill the bacterial cells, both inside and outside of host cells. The compositions may further include supramolecular structures (e.g., liposomes) that target the host cell, e.g., macrophage or dendritic cell, and the correct targeted intracellular compartment (endosome, phagosome, lysosome, or cytosol), to target the intracellular life cycle phase. The liposome directs the payload to the correct cell type and intracellular compartment, while the cocktail of antibacterial lytic proteins degrades the mycobacterial envelope. The free form of the enzymes can degrade the envelope from outside in, while the internalized supramolecular structures can degrade the envelope from inside out to kill the bacteria.

The compositions described herein include a cocktail containing two or more of Lysin A, Lysin B, isoamylase, and a-amylase. Such a combination of lytic proteins is particularly advantageous in killing a mycobacterial cell and related actinomycetia. To come up with the protein components we first rationally attacked three layers of the mycobacterial envelope, the capsule, the junction between the mycolic acids and the AGL layer, and the peptidoglycan layer. The components of envelopes at the basic structure levels are observed for many actinomycetia, such as corynebacteriales (e.g., mycobacteria) and propionibacteriales, such as cutibacteria.

These thermostable complexes exhibit robust antimycobacterial effects and can be used to treat infections caused by a variety of mycobacteria and related actinomycetia (e.g., corynebacteriales or propionibacteriales) with similar envelope structures.

Antibacterial lytic proteins

The invention features compositions containing one or more of (e.g., one, two, three, or four) of Lysin A, Lysin B, isoamylase, and a-amylase. The invention also features a composition containing unencapsulated proteins that contains two or more of (e.g., two, three, or four) Lysin A, Lysin B, isoamylase, and a-amylase. The invention also features compositions that further include a supramolecular complex (e.g., liposome) containing one or more of (e.g., one, two, three, or four) of Lysin A, Lysin B, isoamylase, and a-amylase. Suitable lytic proteins for incorporation into the compositions described herein are shown below in Table 1 . These proteins exhibit improved expression, thermal stability, and antibacterial effects, e.g., as compared to other orthologs of these proteins. Table 1. Lytic protein sequences

The compositions described herein may include a Lysin A that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2. The Lysin A may include or consist of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2.

The compositions described herein may include a Lysin B that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184. The Lysin B may include or consist of the amino acid sequence of SEQ ID NO: 183 or SEQ ID NO: 184.

The compositions described herein may include an isoamylase that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243. The isoamylase may include or consist of the amino acid sequence of SEQ ID NO: 242 or SEQ ID NO: 243.

The compositions described herein may include an a-amylase that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to any one of SEQ ID NOs: 393-398. The a-amylase may include or consist of the amino acid sequence of any one of SEQ ID NOs: 393-398.

The compositions described herein may include an a-amylase that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to SEQ ID NO: 393 or SEQ ID NO: 394. The a-amylase may include or consist of the amino acid sequence of SEQ ID NO: 393 or SEQ ID NO: 394.

Additional sequences were identified that may be useful in the compositions and methods described herein. In some embodiments, the composition includes a Lysin A that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to of any one of SEQ ID NOs: 1 -182 as shown in Table 2 below. Table 2. Lysin A Sequences

Additional sequences were identified that may be useful in the compositions and methods described herein. In some embodiments, the composition includes a Lysin B that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to of any one of SEQ ID NOs: 183-241 as shown in Table 3 below.

Table 3. Lysin B Sequences

Additional sequences were identified that may be useful in the compositions and methods described herein. In some embodiments, the composition includes an isoamylase that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to of any one of SEQ ID NOs: 242-392 as shown in Table 4 below. Table 4. Isoamylase Sequences

Additional sequences were identified that may be useful in the compositions and methods described herein. In some embodiments, the composition includes an a-amylase that includes an amino acid sequence having at least 85% (e.g., at least 90%, 95%, 97%, 99%, or 100%) sequence identity to of any one of SEQ ID NOs: 393-445 as shown in Table 5 below.

Table 5. a-amylase Sequences

One of skill in the art would appreciate that the lytic proteins described herein may be recombinantly produced. Accordingly, the protein may contain a suitable purification tag, such as a His tag containing, e.g., three, four, five, six, seven, eight, nine, ten, or more histidine residues present at the N-terminus or C-terminus of the protein. The protein may also contain a removable signal sequence present at the N-terminus or C-terminus of the protein.

One of skill in the art would also appreciate that the lytic proteins described herein may include biologically active fragments thereof, e.g., fragments of a lytic protein as described herein that may be truncated, e.g., by 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, or more amino acids but still substantially retain their biological activity.

In some embodiments, one or more of the lytic proteins (e.g., unencapsulated proteins) is mannosylated. Such mannosylation may allow the protein to be targeted to an intracellular destination, e.g., within an antigen presenting cell.

1 mg/mL, e.g., 0.1 mg/mL, 0.2 mg/mL, 0.3 mg/mL, 0.4 mg/mL, 0.5 mg/mL, 0.6 mg/mL, 0.7 mg/mL, 0.8 mg/mL, 0.9 mg/mL, or 1 mg/mL, e.g., from 1 mg/mL to 10 mg/mL, e.g., 2 mg/mL, 3 mg/mL, 4 mg/mL, 5 mg/mL, 6 mg/mL, 7 mg/mL, 8 mg/mL, 9 mg/mL, 10 mg/mL, e.g., from 10 mg/mL to 20 mg/mL, e.g., 11 mg/mL, 12 mg/mL, 13 mg/mL, 14 mg/mL, 15 mg/mL, 16 mg/mL, 17 mg/mL, 18 mg/mL, 19 mg/mL, or 20 mg/mL). In some embodiments, the composition includes a concentration of Lysin A, Lysin B, isoamylase, and/or a-amylase of from 1 mg/mL to 10 mg/mL.

Bacterial Infections

The compositions described herein are useful for treating bacterial infections. In some embodiments, the compositions described herein target bacteria that reside extracellularly for at least a portion of their life cycle. In some embodiments, the compositions described herein target bacteria that reside intracellularly for at least a portion of their life cycle. Intracellular bacteria reside within a host cell where they reproduce and cause infection. Intracellular bacteria may reside within immune cells, such as professional antigen cells. Professional antigen presenting cells (APCs) include macrophages, dendritic cells, and phagocytic cells, such as macrophages. APCs process and display antigens complexed with major histocompatibility complexes (MHCs) on their surfaces. APCs put antigens up on MHC class 2 for bacterial pathogens, which are recognized by T cells, which then go onto stimulate B cells that have nd antibody that is complementary to the antigen. This leads to proliferation of the specific B cells that encode for the specific antibody to combat organisms that have that antigen. Certain bacteria evade this immune response by hiding within the immune cell.

The compositions and methods described herein may be used to target a mycobacterium, such as an intracellular mycobacterium that resides in a professional antigen presenting cell (e.g., macrophage or dendritic cell). In some embodiments, the mycobacterial species is M. tuberculosis, M. leprae, M. lepromatosis, M. avium, M. kansasii, M. fortuitum, M. chelonae, M. marinum, M. intracellulare, M. abscessus, M. chimera, M. boletti, M. fortuitum, M. goodii, or M. masiliense. In particular embodiments, the mycobacterium is an NTM. In some embodiments, the NTM is M. abscessus, M. intracellulare, M. avium, M. chimera, M. boletti, M. fortuitum, M. goodii, and M. masiliense.

In some embodiments, the compositions and methods described herein may be used to target other actinomycetia (e.g., corynebacteriales or propionibacteriales) that have similar envelope components as mycobacteria. For example, the compositions and methods may be used to target a Nocardia, Corynebacterium, or Rhodococcus species. For example, the Nocardia species may be, e.g., N. brasiliensis, N. cyriacigeorgica, N. farcinica, N. nova, N. asteroids, N. brasiliensis, and N. caviae. The Corynebacterium species may be, e.g., C. glutamicum or C. diphtheriae. The Rhodococcus species may be, e.g., R. fascians or R. equi. The composition and methods may be used to target a propionibacteriales, such as a Cutibacterium species. The Cutibacterium species may be, e.g., C. acnes.

Supramolecular Structures

Supramolecular structures may be used to formulate a cocktail of lytic enzymes for delivery. Supramolecular structures include a defined complex of molecules, e.g., lipids, held together by non- covalent bonds, such as hydrogen bonds, van der Waals forces, electrostatic interactions, ion-dipole forces, hydrophobic effect, and pi-pi interactions. Supramolecular structures may include large complexes of molecules that form sphere-, rod-, helix-, or sheet-like structures. Supramolecular structures include, for example, lipid-based supramolecular structures, such as micelles, liposomes, and LNPs. Supramolecular structures may have a pre-determined size. The size of the structure may vary based on the components, e.g., size of protein, packed within the structure. The supramolecular complex is endocytosed by a cell, e.g., a professional antigen presenting cell such as a macrophage or dendritic cell, and the antibacterial lytic proteins are delivered to the targeted intracellular compartment (endosome, phagosome, lysosome, or cytosol) wherein the bacteria reside.

In some embodiments, a particular particle size is used to access a certain endocytic route to direct the structure to the appropriate targeted intracellular compartment. The supramolecular structure may be endocytosed and delivered to the targeted intracellular compartment, e.g., via clathrin-dependent endocytosis or via caveolin-dependent endocytosis. The particle size, e.g., Z- average mean particle diameter, of the supramolecular structure may vary from 75 nm to 5 pm, e.g., from 75 nm to 2 pm, from 75 nm to 1 pm, e.g. from 75 nm to 750 nm (e.g., from 250 nm to 750 nm, or from 75 nm to 250 nm). In some embodiments, when the supramolecular structure is an LNP or micelle, the Z-average mean particle diameter is from 75 nm to 250 nm. In some embodiments, when the supramolecular structure is a vesicle (e.g., a liposome), the Z-average mean particle diameter is from 250 nm to 750 nm. Non-limiting examples of the Z-average mean particle diameters include, e.g., from 75 nm to 100 nm, e.g., from 75 nm to 85 nm, e.g., 80 nm, e.g., from 80 nm to 140 nm, from 90 nm to 130 nm, or from 110 nm to 130 nm, e.g., 120 nm, e.g., from 200 nm to 300 nm, e.g., from 250 nm to 300 nm, from 260 nm to 290 nm, from 260 nm to 280 nm, from 265 nm to 275 nm, e.g., 270 nm, e.g., from 300 nm to 400 nm, from 400 nm to 600 nm, e.g., from 450 nm to 550 nm, from 475 nm to 525 nm, from 480 nm to 520 nm, from 490 nm to 510 nm, from 495 nm to 505 nm, e.g., 500 nm, e.g., 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, 130 nm, 135 nm, 140 nm, 145 nm, 150 nm, 155 nm, 160 nm, 165 nm, 170 nm, 175 nm, 180 nm, 185 nm, 190 nm, 195 nm, 200 nm, 205 nm, 210 nm, 215 nm, 220 nm, 225 nm, 230 nm, 235 nm, 240 nm,

245 nm, 250 nm, 255 nm, 260 nm, 265 nm, 270 nm, 275 nm, 280 nm, 285 nm, 290 nm, 295 nm, 300 nm, 305 nm, 310 nm, 315 nm, 320 nm, 325 nm, 330 nm, 335 nm, 340 nm, 345 nm, 350 nm, 355 nm,

360 nm, 365 nm, 370 nm, 375 nm, 380 nm, 385 nm, 390 nm, 395 nm, 400 nm, 405 nm, 410 nm, 415 nm, 420 nm, 425 nm, 430 nm, 435 nm, 440 nm, 445 nm, 450 nm, 455 nm, 460 nm, 465 nm, 470 nm,

475 nm, 480 nm, 485 nm, 490 nm, 495 nm, 500 nm, 505 nm, 510 nm, 515 nm, 520 nm, 525 nm, 530 nm, 535 nm, 540 nm, 545 nm, 550 nm, 555 nm, 560 nm, 565 nm, 570 nm, 575 nm, 580 nm, 585 nm,

590 nm, 595 nm, 600 nm, 605 nm, 610 nm, 615 nm, 620 nm, 625 nm, 630 nm, 635 nm, 640 nm, 645 nm, 650 nm, 655 nm, 660 nm, 665 nm, 670 nm, 675 nm, 680 nm, 685 nm, 690 nm, 695 nm, 700 nm,

705 nm, 710 nm, 715 nm, 720 nm, 725 nm, 730 nm, 735 nm, 740 nm, 745 nm, 750 nm, 755 nm, 760 nm, 765 nm, 770 nm, 775 nm, 780 nm, 785 nm, 790 nm, 795 nm, 800 nm, 805 nm, 810 nm, 815 nm,

820 nm, 825 nm, 830 nm, 835 nm, 840 nm, 845 nm, 850 nm, 855 nm, 860 nm, 865 nm, 870 nm, 875 nm, 880 nm, 885 nm, 890 nm, 895 nm, 900 nm, 905 nm, 910 nm, 915 nm, 920 nm, 925 nm, 930 nm,

935 nm, 940 nm, 945 nm, 950 nm, 955 nm, 960 nm, 965 nm, 970 nm, 975 nm, 980 nm, 985 nm, 990 nm, 995 nm, 1 pm, 1.1 pm, 1.2 pm, 1.3 pm, 1.4 pm, 1.5 pm, 1.6 pm, 1.7 pm, 1.8 pm, 1.9 pm, 2 pm, 2.1 pm, 2.2 pm 2.3 pm, 2.4 pm, 2.5 pm, 2.6 pm, 2.7 pm, 2.8 pm, 2.9 pm, 3 pm, 3.1 pm, 3.2 pm, 3.3 pm, 3.4 pm, 3.5 pm, 3.6 pm, 3.7 pm, 3.8 pm, 3.9 pm, 4 pm, 4.1 pm 4.2 pm 4.3 pm, 4.4 pm, 4.5 pm, 4.6 pm, 4.7 pm, 4.8 pm, 4.9 pm, or 5 pm. In particular embodiments, the Z-average mean particle diameter of the supramolecular structure may be from 75 nm to 250 nm. In some embodiments, the Z-average mean particle diameter of the supramolecular structure is 80 nm, 270 nm, or 500 nm.

The mean particle diameter may be measured by zeta potential, dynamic light scattering (DLS), electrophoretic light scattering (ELS), static light scattering (SLS), molecular weight, electrophoretic mobility, size exclusion chromatography (SEC), field flow fractionation, or other methods known in the art. In particular embodiments, the mean particle diameter is measured by. In particular embodiments, the supramolecular structure contains a Z-average mean particle diameter of from 75 nm to 250 nm. In particular embodiments, the supramolecular structure contains a Z-average mean particle diameter of from 250 nm to 750 nm. In particular embodiments, the supramolecular structure contains a Z-average mean particle diameter of 500 nm. In particular embodiments, the supramolecular structure contains a Z-average mean particle diameter of 270 nm. In particular embodiments, the supramolecular structure contains a Z-average mean particle diameter of 80 nm. One of skill in the art would appreciate that a population of supramolecular structures (e.g., liposomes, LNPs, or micelles) may have a range of Z-average mean particle diameters within the population. Thus, the population may be polydisperse. The population may have a polydispersity index of 0.5 or less, e.g., 0.3 or less (e.g., 0.05 to 0.3). The polydispersity index can be determined using DLS (see, e.g., ISO 22412:2017).

The supramolecular structures may be loaded with a predetermined number of antibacterial lytic proteins or average number of antibacterial lytic proteins per supramolecular structure. For example, the supramolecular structure may contain from one protein to 10⁶ proteins (e.g., 1 to 10⁵, 1 to 10⁴, 1 to 10³, 1 to 10², 1 to 10, 10 to 10^e, 10 to 10⁵,10 to 10⁴, 10 to 10³, 10 to 10², 10³ to 10^e, 10³ to 10⁵, 10³ to 10⁴). The number of proteins per structure may depend on the size of the protein and the size of the structure.

The supramolecular structures may include an endosomal escape moiety. Supramolecular structures including an endosomal escape moiety may provide for an improved cytosolic delivery of the cargo (e.g., a therapeutic agent) included in the supramolecular structure. Endosomal escape moieties are known in the art. In some embodiments, an endosomal escape moiety is an ionizable lipid. The ionizable lipids may also serve as supramolecular structure-layer forming lipids. Nonlimiting examples of ionizable lipids include those described in, e.g., WO 2019/067875; WO 2018/191750; and US 9,999,671 . Other exemplary endosomal escape moieties include fusogenic lipids (e.g., dioleoylphosphatidyl-ethanolamine (DOPE)); and polymers such as polyethylenimine (PEI); poly(beta-amino ester)s; polypeptides, such as polyarginines (e.g., octaarginine) and polylysines (e.g., octalysine); proton sponges, viral capsids, and peptide transduction domains as described herein. For example, fusogenic peptides can be derived from the M2 protein of influenza A viruses; peptide analogs of the influenza virus hemagglutinin; the HEF protein of the influenza C virus; the transmembrane glycoprotein of filoviruses; the transmembrane glycoprotein of the rabies virus; the transmembrane glycoprotein (G) of the vesicular stomatitis virus; the fusion protein of the Sendai virus; the transmembrane glycoprotein of the Semliki forest virus; the fusion protein of the human respiratory syncytial virus (RSV); the fusion protein of the measles virus; the fusion protein of the Newcastle disease virus; the fusion protein of the visna virus; the fusion protein of murine leukemia virus; the fusion protein of the HTL virus; and the fusion protein of the simian immunodeficiency virus (SIV). Other moieties that can be employed to facilitate endosomal escape are described in Dominska et al., Journal of Cell Science, 123(8): 1183-1189, 2010. Specific examples of endosomal escape moieties including moieties suitable for inclusion in, or conjugation to, to the supramolecular structures disclosed herein are provided, e.g., in WO 2015/188197; the disclosure of these endosomal escape moieties is incorporated by reference herein.

Liposomes

Liposomes are useful for the transfer and delivery of antibacterial proteins to the site of action. Because the liposomal membrane is structurally similar to biological membranes, when liposomes are applied to a tissue, the liposomal bilayer fuses with bilayer of the cellular membranes, e.g., intracellular membranes. In some instances, prior to fusing with biological membranes, the liposomes are phagocytosed to form multilamellar vesicles, which may then fuse with phagolysosomes, e.g., phagolysosomes containing mycobacteria. As the merging of the liposome and phagolysosome progresses, the internal aqueous contents that include the antibacterial protein are delivered into the phagolysosome where the antibacterial protein can specifically target and lyse a bacterial cell (e.g., mycobacterial cell, e.g., NTM cell) residing inside a mammalian immune cell. In some cases, the liposomes are also specifically targeted, e.g., to direct the protein to particular mammalian immune cell types and/or to particular intracellular compartments that typically harbor bacteria (e.g., mycobacteria) during infection (endosome, phagosome, lysosome, or cytosol). The composition of the liposome is usually a combination of phospholipids, usually in combination with steroids, such as cholesterol. Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.

In some embodiments, a liposome described herein includes a phospholipid. In some embodiments, a glycerophospholipid, e.g., a phosphatidylserine. A phosphatidylserine is a glycerol molecule having two hydroxyl groups substituted with fatty acid ester moieties and one hydroxyl group substituted with a phosphodiester moiety that is covalently bonded to serine side chain. A typical structure of a phosphatidylserine is RO-CH2-CH(OR)-CH2-OP(O)(OH)-OCH2CH(COOH)NH2, or a salt thereof, where each R is independently a fatty acid acyl. Additionally, or alternatively, a liposome described herein may include, e.g., a lysophospholipid, e.g., a lysophosphatidylserine. A lysophosphatidylserine is a phosphatidylserine missing one of its two fatty acid ester moieties. A typical structure of a lysophosphatidylserine is RO-CH2-CH(OR)-CH2-OP(O)(OH)- OCH2CH(COOH)NH2, or a salt thereof, where one R is a fatty acid acyl, and the other R is H. Thus, in certain preferred embodiments, a liposome described herein includes RO-CH2-CH(OR)-CH2- OP(O)(OH)-OCH2CH(COOH)NH2, or a salt thereof, where each R is H or a fatty acid acyl, provided that at least one R is a fatty acid acyl. One major type of liposomal composition includes phospholipids other than naturally derived phosphatidylcholine. Neutral liposome compositions, for example, can be formed from dimyristoyl phosphatidylcholine (DMPC) or dipalmitoyl phosphatidylcholine (DPPC). Cationic liposomes possess the advantage of being able to fuse to the cell membrane. Non-limiting examples of cationic lipids include N,N-dioleyl-N,N-dimethylammonium chloride (DODAC), N,N-distearyl-N,N-dimethylammonium bromide (DDAB), N--(l-(2,3-dioleoyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTAP), N-(l- (2,3-dioleyloxy)propyl)-N,N,N-trimethylammonium chloride (DOTMA), N,N-dimethyl-2,3- dioleyloxy)propylamine (DODMA), 1 ,2-DiLinoleyloxy-N,N-dimethylaminopropane (DLinDMA), 1 ,2- Dilinolenyloxy-N,N-dimethylaminopropane (DLenDMA), 1 ,2-Dilinoleylcarbamoyloxy-3- dimethylaminopropane (DLin-C-DAP), 1 ,2-Dilinoleyoxy-3-(dimethylamino)acetoxypropane (DLin- DAC), 1 ,2-Dilinoleyoxy-3-morpholinopropane (DLin-MA), 1 ,2-Dilinoleoyl-3-dimethylaminopropane (DLinDAP), 1 ,2-Dilinoleylthio-3-dimethylaminopropane (DLin-S-DMA), 1-Linoleoyl-2-linoleyloxy-3- dimethylaminopropane (DLin-2-DMAP), 1 ,2-Dilinoleyloxy-3-trimethylaminopropane chloride salt (DLin- TMA.CI), 1 ,2-Dilinoleoyl-3-trimethylaminopropane chloride salt (DLin-TAP.CI), 1 ,2-Dilinoleyloxy-3-(N- methylpiperazino)propane (DLin-MPZ), or 3-(N,N-Dilinoleylamino)-1 ,2-propanediol (DLinAP), 3-(N,N- Dioleylamino)-1 ,2-propanedio (DOAP), 1 ,2-Dilinoleyloxo-3-(2-N,N-dimethylamino)ethoxypropane (DLin-EG-DMA), 1 ,2-Dilinolenyloxy-N,N-dimethylaminopropane (DLinDMA), 2,2-Dilinoleyl-4- dimethylaminomethyl-[1 ,3]-dioxolane (DLin-K-DMA) or analogs thereof, (3aR,5s,6aS)-N,N-dimethyl- 2,2-di((9Z,12Z)-octadeca-9,12-dienyetetrahydro- 3aH-cyclopenta[d][1 ,3]dioxol-5-amine (ALN100), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl4-(dimethylamino)butanoate (MC3), 1 ,1'-(2-(4- (2-((2-(bis(2-hydroxydodecyl)amino)ethyl)(2-hydroxydodecyl)amino)ethyl)piperazin-1- yeethylazanediyedidodecan-2-ol (Tech G1), or a mixture thereof. The cationic lipid can include, for example, from 20 mol % to 50 mol % or 40 mol % of the total lipid present in the particle.

Non-cationic liposomes may be taken up by macrophages in vivo and can be used to deliver antibacterial proteins to macrophages. Anionic liposome compositions may be formed from dimyristoyl phosphatidylglycerol, while anionic fusogenic liposomes may be formed primarily from dioleoyl phosphatidylethanolamine (DOPE). The lipid can be an anionic lipid or a neutral lipid including, but not limited to, distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1 -carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl- phosphatidyl-ethanolamine (DSPE), 16-O-monomethyl PE, 16-O-dimethyl PE, 18-1 -trans PE, 1- stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), cholesterol, 1 ,2-dioleoyl-sn-glycero-3-phospho-L- serine (sodium salt, DOPS), or a mixture thereof. The non-cationic lipid can be, for example, from 5 mol % to 90 mol %, 10 mol %, or 58 mol % if cholesterol is included, of the total lipid present in the particle. In some embodiments, a lipid can be a combination of lipids described above, e.g., a combination of lipids including DOPC, DOPS, Choi, and DOPE. In some embodiments, the liposome includes a mixture of lipids. For example, the mixture of lipids may include two or more of DOPC, DOPE, DOPS, and cholesterol.

In some embodiments, the DOPC and DOPE are present at a molar ration of from 10:1 to 1:10 (e.g., 10:1 , 9:1 , 8:1 , 7:1 , 6:1 , 5:1 , 4:1 , 3:1 , 2:1 , 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10).

In some embodiments, the DOPE and cholesterol are present at a molar ratio of from 10:1 to 1:10 (e.g., 10:1 , 9:1 , 8:1 , 7:1 , 6:1 , 5:1 , 4:1 , 3:1 , 2:1 , 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10).

In some embodiments, the DOPS and cholesterol are present at a molar ratio of from 10:1 to 1:10 (e.g., 10:1 , 9:1 , 8:1 , 7:1 , 6:1 , 5:1 , 4:1 , 3:1 , 2:1 , 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10).

In some embodiments, the DOPC, DOPE, DOPS, and cholesterol are present at a molar ratio of from 1-20:1-20:1-5:1-5. For example, in some embodiments, the DOPC, DOPE, DOPS, and cholesterol are present at a molar ratio of 10:10:3:4.

In some embodiments, the liposome includes a concentration of lipids of from 0.03 mg/mL to 10 mg/mL, e.g., 0.1 mg/mL to 10 mg/mL (e.g., from 0.1 mg/mL to 1 mg/mL, e.g., 0.1 mg/mL, 0.2 mg/mL, 0.3 mg/mL, 0.4 mg/mL, 0.5 mg/mL, 0.6 mg/mL, 0.7 mg/mL, 0.8 mg/mL, 0.9 mg/mL, or 1 mg/mL, e.g., from 1 mg/mL to 10 mg/mL, e.g., 2 mg/mL, 3 mg/mL, 4 mg/mL, 5 mg/mL, 6 mg/mL, 7 mg/mL, 8 mg/mL, 9 mg/mL, or 10 mg/mL). In some embodiments, the liposome includes a concentration of lipids of from 1 mg/mL to 5 mg/mL.

Another type of liposomal composition is formed from phosphatidylcholine (PC) such as, for example, soybean PC, and egg PC. Another type is formed from mixtures of phospholipid and/or phosphatidylcholine and/or cholesterol. Examples of other methods to introduce liposomes into cells in vitro and in vivo include U.S. Pat. No.5,283,185; U.S. Pat. No.5,171,678; WO 94/00569; WO 93/24640; WO 91/16024; Feigner, (1994) J. Biol. Chem.269:2550; Nabel, (1993) Proc. Natl. Acad. Sci.90:11307; Nabel, (1992) Human Gene Ther.3:649; Gershon, (1993) Biochem.32:7143; and Strauss, (1992) EMBO J. 11:417.

The targeting of liposomes is also possible based on, for example, organ-specificity, cell-specificity, and organelle-specificity and is known in the art. In the case of a liposomal targeted delivery system, lipid groups can be incorporated into the lipid bilayer of the liposome in order to maintain the targeting ligand in stable association with the liposomal bilayer. Various linking groups can be used for joining the lipid chains to the targeting ligand. Additional methods are known in the art and are described, for example in U.S. Pub. No.20060058255, the linking groups of which are herein incorporated by reference.

Cleavable linking groups are susceptible to cleavage agents, e.g., pH, redox potential, or the presence of degradative molecules. Generally, cleavage agents are more prevalent or found at higher levels or activities inside cells than in serum or blood. Examples of such degradative agents include: redox agents which are selective for particular substrates or which have no substrate specificity, including, e.g., oxidative or reductive enzymes or reductive agents such as mercaptans, present in cells, that can degrade a redox cleavable linking group by reduction; esterases; endosomes or agents that can create an acidic environment, e.g., those that result in a pH of five or lower; enzymes that can hydrolyze or degrade an acid cleavable linking group by acting as a general acid; peptidases (which can be substrate specific); and phosphatases.

A cleavable linkage group, such as a disulfide bond can be susceptible to pH. The pH of human serum is 7.4, while the average intracellular pH is slightly lower, ranging from 7.1 -7.3. Endosomes have a more acidic pH, in the range of 5.5-6.0, and lysosomes have an even more acidic pH at around 5.0. Some linkers will have a cleavable linking group that is cleaved at a preferred pH, thereby releasing a cationic lipid from the ligand inside the cell, or into the desired compartment of the cell.

A linker can include a cleavable linking group that is cleavable by a particular enzyme. The type of cleavable linking group incorporated into a linker can depend on the cell to be targeted. In general, the suitability of a candidate cleavable linking group can be evaluated by testing the ability of a degradative agent (or condition) to cleave the candidate linking group. It will also be desirable to also test the candidate cleavable linking group for the ability to resist cleavage in the blood or when in contact with other non-target tissues. Thus, one can determine the relative susceptibility to cleavage between a first and a second condition, where the first is selected to be indicative of cleavage in a target cell and the second is selected to be indicative of cleavage in other tissues or biological fluids, e.g., blood or serum. The evaluations can be carried out in cell free systems, in cells, in cell culture, in organ or tissue culture, or in whole animals. It can be useful to make initial evaluations in cell-free or culture conditions and to confirm by further evaluations in whole animals. In preferred embodiments, useful candidate linkers are cleaved at least 2, 4, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 times faster in the cell (or under in vitro conditions selected to mimic intracellular conditions) as compared to blood or serum (or under in vitro conditions selected to mimic extracellular conditions).

Lipid Nanoparticles

Anti-bacterial agents of in the invention may be fully encapsulated in a lipid formulation, e.g., a lipid nanoparticle (LNP). LNPs are extremely useful for systemic applications, as they exhibit extended circulation lifetimes following intravenous (i.v.) injection and accumulate at distal sites (e.g., sites physically separated from the administration site). LNPs include "pSPLP," which include an encapsulated condensing agent-nucleic acid complex as set forth in PCT Publication No. WO 2000/003683. The particles of the present invention typically have a mean diameter of 50 nm to 150 nm, more typically 60 nm to 130 nm, more typically 70 nm to 110 nm, most typically 70 nm to 90 nm, and are substantially nontoxic. In addition, the nucleic acids when present in the nucleic acid-lipid particles of the present invention are resistant in aqueous solution to degradation with a nuclease. Nucleic acid-lipid particles and their method of preparation are disclosed in, e.g., U.S. Pat. Nos. 5,976,567; 5,981 ,501 ; 6,534,484; 6,586,410; 6,815,432; U.S. Publication No. 2010/0324120 and PCT Publication No. WO 96/40964. In one embodiment, the lipid to drug ratio (mass/mass ratio) (e.g., lipid to peptide ratio) will be in the range of from 1:1 to 50:1, from 1:1 to 25:1, from 3:1 to 15:1, from 4:1 to 10:1, from 5:1 to 9:1, or 6:1 to 9:1. Ranges intermediate to the above recited ranges are also contemplated to be part of the invention.

Non-limiting examples of cationic lipids include DODAC, DDAB, DOTAP, DOTMA, DODMA, DLinDMA, DLenDMA, DLin-C-DAP, DLin-DAC, DLin-MA, DLinDAP, DLin-S-DMA, DLin-2-DMAP, DLin-TMA.CI, DLin-TAP.CI, 1DLin-MPZ, DLinAP, DOAP, DLin-EG-DMA, (DLin-K-DMA or analogs thereof, ALN100, MC3, Tech G1 , or a mixture thereof. The cationic lipid can include, for example, from 20 mol % to 50 mol % or 40 mol % of the total lipid present in the particle.

The lipid can be an anionic lipid or a neutral lipid including, but not limited to, DSPC, DOPC, DOPS, DPPC, DOPG, DPPG, DOPE, POPC, POPE, DOPE-mal, DPPE, DMPE, DSPE, 16-0- monomethyl PE, 16-O-dimethyl PE, 18-1 -trans PE, SOPE, cholesterol, ora mixture thereof. The noncationic lipid can be, for example, from 5 mol % to 90 mol %, 10 mol %, or 60 mol % if cholesterol is included, of the total lipid present in the particle.

The conjugated lipid that inhibits aggregation of particles can be, for example, a polyethyleneglycol (PEG)-lipid including, without limitation, a PEG-diacylglycerol (DAG), a PEG- dialkyloxypropyl (DAA), a PEG-phospholipid, a PEG-ceramide (Cer), or a mixture thereof. The PEG- DAA conjugate can be, for example, a PEG-dilauryloxypropyl (C12), a PEG-dimyristyloxypropyl (C14), a PEG-dipalmityloxypropyl (Cie), or a PEG-distearyloxypropyl (Cis). The conjugated lipid that prevents aggregation of particles can be, for example, from 0 mol % to 20 mol % or 2 mol % of the total lipid present in the particle.

In some embodiments, the LNP further includes cholesterol at, e.g., 10 mol % to 60 mol % or 50 mol % of the total lipid present in the particle.

In some embodiments, the LNP includes a mixture of lipids. For example, the mixture of lipids may include two or more of DOPC, DOPE, DOPS, and cholesterol.

In some embodiments, the DOPC and DOPE are present at a molar ratio of from 10:1 to 1:10 (e.g., 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10).

In some embodiments, the DOPC and DOPS are present at a molar ratio of from 10:1 to 1:10 (e.g., 10:1, 9:1, 8:1, 7:1, 6:1, 5:1, 4:1, 3:1, 2:1, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, or 1:10).

In some embodiments, the DOPC, DOPE, DOPS, and cholesterol are present at a molar ratio of from 1-20:1-20:1-5:1-5. For example, in some embodiments, the DOPC, DOPE, DOPS, and cholesterol are present at a molar ratio of 10:10:3:4. In some embodiments, the LNP includes a concentration of lipids of from 0.03 mg/mL to 10 mg/mL, e.g., 0.1 mg/mL to 10 mg/mL (e.g., from 0.1 mg/mL to 1 mg/mL, e.g., 0.1 mg/mL, 0.2 mg/mL, 0.3 mg/mL, 0.4 mg/mL, 0.5 mg/mL, 0.6 mg/mL, 0.7 mg/mL, 0.8 mg/mL, 0.9 mg/mL, or 1 mg/mL, e.g., from 1 mg/mL to 10 mg/mL, e.g., 2 mg/mL, 3 mg/mL, 4 mg/mL, 5 mg/mL, 6 mg/mL, 7 mg/mL, 8 mg/mL, 9 mg/mL, or 10 mg/mL). In some embodiments, the LNP includes a concentration of lipids of from 1 mg/mL to 5 mg/mL.

Micelles

Micelles are a particular type of molecular assembly in which amphipathic molecules are arranged in a spherical structure such that all the hydrophobic portions of the molecules are directed inward, leaving the hydrophilic portions in contact with the surrounding aqueous phase. Micelles may be made of lipids. The micelle phase is caused by the packing behavior of single-tail lipids in a bilayer. The difficulty filling all the volume of the interior of a bilayer, while accommodating the area per head group forced on the molecule by the hydration of the lipid head group, leads to the formation of the micelle. This type of micelle is known as a normal-phase micelle (oil-in-water micelle). Inverse micelles have the head groups at the center with the tails extending out (water-in-oil micelle).

Micelles are approximately spherical in shape. Other phases, including shapes such as ellipsoids, cylinders, and bilayers, are also possible. The shape and size of a micelle are a function of the molecular geometry of its surfactant molecules and solution conditions such as surfactant concentration, temperature, pH, and ionic strength. The process of forming micelles is known as micellization and forms part of the phase behavior of many lipids according to their polymorphism.

Targeting Moieties

A supramolecular structure described herein may include, e.g., a targeting moiety. A targeting moiety may be used to direct the supramolecular structure to a particular cell-type (e.g., a professional antigen-presenting cell, e.g., macrophage or dendritic cell). Certain lipids (e.g., phosphatidyl serine) may be used in the supramolecular structure (e.g., a vesicle) both as a supramolecular structure layer-forming lipid and as a targeting moiety. The targeting moiety may be, e.g., an antibody or an antigen-binding fragment or an engineered derivative thereof (e.g., Fcab or a fusion protein (e.g., scFv)). The targeting moiety may be, e.g., a polypeptide. Alternatively, the targeting moiety may be, e.g., a small molecule (e.g., mannose or folate) or a cluster of small molecules (e.g., a cluster of mannoses). A targeting moiety may be associated with a supramolecular structure covalently or non-covalently.

Small Molecules

The targeting moiety may be a small molecule capable of complexing a receptor expressed on the surface of the targeted cell. Non-limiting examples of small molecules that may be used as targeting moieties in the supramolecular structures described herein are phosphatidylserine, lysophosphatidylserine folate, mannose, and mannose clusters. In some embodiments, the targeting moiety is phosphatidylserine or lysophosphatidylserine.

In some embodiments, the targeting moiety is phosphatidylserine. Phosphatidylserine and/or lysophosphatidylserine may be present as a supramolecular structure layer-forming lipid that is non- covalently bonded to the rest of the supramolecular structure.

Folate may be used as a targeting moiety. In the supramolecular structures described herein, folate may be of the following structure:

Mannose or a mannose cluster can be used to target the supramolecular structure described herein to dendritic cells and macrophages. Mannose clusters are known in the art.

Folate, mannose, and mannose clusters may be covalently linked to the supramolecular structure. Conjugation techniques for linking folate, mannose, and mannose clusters are known in the art, for example, as described in US 2014/0045919, US 9,725,479, US 8,758,810, US 8,450,467, US 6,525,031 , US 6,335,434, and US 5,759,572.

Antigen-Binding Moieties

An antigen-binding moiety in the supramolecular structure described herein can be an antibody or an antigen-binding fragment thereof, e.g., F(ab)2 or Fab, or an engineered derivative thereof, e.g., Fcab or a fusion protein, e.g., scFv. A human or chimeric, e.g., humanized, antibody can be used as an antibody in the supramolecular structure described herein.

The antigen-binding moiety targets APCs having the surface antigen that is recognized by the antigen-binding moiety. Dendritic cells may be targeted by anti-DEC205, anti-CD304, anti-CD303, anti-CD40, anti-CD74, anti-BDCA2, or anti-CD123 antibodies or antigen-binding fragments thereof or engineered derivatives thereof. Macrophages can be targeted by anti-CD163, anti-CD40, anti-CD74, anti-CD206, or anti-CD123 antibodies or antigen-binding fragments thereof or engineered derivatives thereof.

Non-limiting examples of anti-CD38 antibodies are daratumumab, SAR650984, MOR202, or any one of antibodies Ab79, Ab19, Ab43, Ab72, and Ab110 disclosed in WO 2012/092616, the disclosure of these antibodies is incorporated herein by reference. A non-limiting example of an anti- CD79b antibody is huMA79b v28 disclosed in WO 2014/011521. A non-limiting example of an anti- CD22 antibody is 10F4 disclosed in US 2014/0127197. A non-limiting example of an anti-CD20 antibody is rituximab. A non-limiting example of an anti-DEC205 antibody is provided in US 2010/0098704, the antibodies of which are incorporated herein by reference. Non-limiting examples of anti-CD40 antibodies are lucatumumab and dacetuzumab. A non-limiting example of an anti-CD304 antibody is vesencumab. Conjugation techniques for linking antigen-binding moieties are known in the art, for example, as described in Ansell et al., Methods Mol. Med., 25:51-68, 2000; US 2002/0025313; US 6,379,699; and US 5,059,421.

Polypeptides

The targeting moiety can be a polypeptide having an affinity for cells (e.g., having an affinity for a cell type, e.g., a dendritic cell). Non-limiting examples of polypeptides are RGD peptide, rabies virus glycoprotein (RVG), and DC3 peptide. Alternatively, the polypeptide may be a TLR2 agonist, e.g., MALP-2 lipoprotein, MALP-404 lipoprotein, OspA, a porin, LcrV, Hsp60, glycoprotein gH/gL, or glycoprotein gB.

Conjugation techniques for linking peptides are known in the art, for example, as described in Ansell et al., Methods Mol. Med., 25:51-68, 2000; US 2002/0025313; US 6,379,699; and US 5,059,421.

PAMPs

The targeting moiety may be a PAMP. PAMPs are known in the art, e.g., a CpG ODN. CpG ODNs are generally divided into three classes: class A, class B, and class C. Class A CpG ODNs typically contain poly-G tails with phosphorothioate backbones at the 3’- and 5’-termini and a central palindromic sequence including a phosphate backbone. Class A CpG ODNs typically contain CpG within the central palindromic sequence. Class B CpG ODNs typically include fully phosphorothioated backbone, and the sequence at the 5’ end of class B CpG ODNs is often critical for TLR9 activation. Class C CpG ODNs include a fully phosphorothioated backbone with a 3’-end sequence enabling formation of a duplex. A PAMP may be covalently linked to a supramolecular structure using techniques and methods known in the art.

Methods of Assembly

The present invention features supramolecular structures (e.g., a lipid based supramolecular structure, such as a liposome) that include a plurality of enzymes packaged therein. Described herein are methods of assembly to produce structures (e.g., liposomes) containing the enzymes (e.g., Lysin A, Lysin B, isoamylase, and/or a-amylase, e.g., having at least 85% sequence identity to a sequence of Table 1). Individual proteins can be overexpressed in any suitable recombinant expression system (e.g., E. coli) and extracted from the cells via lysis. In some embodiments, the crude extract from the cells may be purified, e.g., via column chromatography. Following purification, enzyme component concentrations may be standardized for subsequent encapsulation, e.g., into liposomes. The concentrations may be standardized, e.g., at from 0.1 mg/mL to 10 mg/mL (e.g., 0.1 mg/mL to 1 mg/mL, e.g., 0.2 mg/mL, 0.3 mg/mL, 0.4 mg/mL, 0.5 mg/mL, 0.6 mg/mL, 0.7 mg/mL, 0.8 mg/mL, 0.9 mg/mL, or 1 mg/mL, e.g., from 1 mg/mL to 10 mg/mL, e.g., 2 mg/mL, 3 mg/mL, 4 mg/mL, 5 mg/mL, 6 mg/mL, 7 mg/mL, 8 mg/mL, 9 mg/mL, or 10 mg/mL). In some embodiments, the concentrations may be standardized at 0.33 mg/mL. Lipids may then be mixed with the enzymes for formulate the liposomes. For example, lipids at a total concentration of 0.1 mg/mL to 10 mg/mL (e.g., 0.1 mg/mL to 1 mg/mL, e.g., 0.2 mg/mL, 0.3 mg/mL, 0.4 mg/mL, 0.5 mg/mL, 0.6 mg/mL, 0.7 mg/mL, 0.8 mg/mL, 0.9 mg/mL, or 1 mg/mL, e.g., from

I mg/mL to 10 mg/mL, e.g., 2 mg/mL, 3 mg/mL, 4 mg/mL, 5 mg/mL, 6 mg/mL, 7 mg/mL, 8 mg/mL, 9 mg/mL, or 10 mg/mL, e.g., from 1 mg/mL to 5 mg/mL) may be mixed with 1 mg/mL to 10 mg/ml His- tagged proteins. The lipids may include, for example, one or more of DOPC, DOPE, DOPS, and cholesterol. In some embodiments, the lipids include DOPC, DOPE, DOPS, and cholesterol in a ratio of 10:10:3:4 ratio. The lipids may be resuspended in a suitable organic solvent (e.g., ethanol) and mixed with the proteins (e.g., at a ratio of from 20:1 to 1 :1 , e.g., 20:1 , 19:1 , 18:1 , 17:1 , 16:1 , 15:1 , 14:1 , 13:1 , 12:1 , 11 :1 , 10:1 , 9:1 , 8:1 , 7:1 , 6:1 , 5:1 , 4:1 , 3:1 , 2:1 , or 1 :1 , e.g., 3:1 to 10:1 , e.g., 3:1 to 8:1 aqueous:organic). The mixture may be mixed at a flow rate of 1 ml/minute to 30 mL/minute, e.g., 15 mL/minute, e.g., using a suitable system, such as the NANOASSEMBLR ® IGNITE™ system (Precision Nanosystems). The organic layer may be removed by dilution and dialysis, e.g., against excess (e.g., 1000X) volumes of formulation buffer, e.g., for at least 30 minutes (e.g., for 1 hour) at a suitable temperature, such as room temperature. Liposomes may then be analyzed by gel electrophoresis (e.g., SDS-PAGE), dynamic light scattering, intrinsic fluorescence, and/or static light scattering and tested for relevant activity. Such assays may help confirm the encapsulation of the enzymes and purity of the enzymes and the liposomes.

The compositions containing the supramolecular structures (e.g., liposomes) may be formulated with one or more excipients. For example, the composition (e.g., a supramolecular structure, e.g., a liposome containing a cocktail of lytic enzymes) may be encapsulated and/or formulated in buffer, such as glycine, Tris, sodium citrate, sodium acetate, and MES, e.g., at a concentration of 10 mM to 200 mM, e.g., 50 mm to 150 mm, e.g., 10 mM, 20 mm, 30 mm, 40 mm, 50 mm, 60 mm, 70 mm, 80 mm, 90 mM, 100 mM, 110 mM, 120 mM, 130 mM, 140 mM, 150 mM, 160 mM, 170 mM, 180 mM, 190 mM, or 200 mM. The composition may be formulated at a pH of from 5 to

I I (e.g., a pH of 5 to 6, e.g., 5.1 , 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, or 6, e.g., 6 to 11 , e.g., 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, or 11). The composition may further include one or more excipients, such as CaCh, arginine, NaCI, sodium citrate, MgCh, or glycerol. In some embodiments, the composition includes, for example, 5 mM to 10 mM CaCh, 0 to 50 mM arginine, 0 to 200 mM NaCI, 0 mM to 1 mM sodium citrate, 0 to 1 mM MgCh, and/or 10-30% glycerol. In some embodiments, the composition includes 50 mM glycine, pH 8.5, 7.5 mM CaCh, 0.5 mM MgCh, 200 mM NaCI, 0.33 mM sodium citrate, and 10% glycerol. The formulation may further include TWEEN, e.g., TWEEN-80. Once the compositions are in a preferred storage or activity buffer, they can be used in treatment or for assays or saved for subsequent use.

Methods of treatment

The antibacterial lytic proteins described herein are preferably formulated into pharmaceutical compositions for administration to human subjects for the treatment of a disease or condition, such as a bacterial infection (e.g., actinomycetia infection, e.g., corynebacteriales or propionibacteriales), e.g., mycobacterial infection, e.g., NTM infection. In particular, the compositions and methods described herein are useful for treating bacterial infections caused by actinomycetia, e.g., corynebacterials and propionibacteriales, due to their similar envelope structure. Bacterial infections may occur in otherwise healthy subjects. Alternatively, the bacterial infection may occur in a subject with another comorbidity or disease. For example, a subject with a weakened immune system may be more susceptible to a bacterial infection.

Mycobacterial infections caused by NTM are bacteria that are normally present in the environment. Inhalation of these bacteria may cause disease in both healthy patients and those with compromised immune systems. NTM disease most often affects the lungs in adults, but it may also affect any body site. Some subjects are at higher risk of getting an NTM infection and developing disease. People who have an existing lung disease such as bronchiectasis (enlargement of airways), chronic obstructive pulmonary disease (COPD), cystic fibrosis, alpha-1 antitrypsin deficiency or who have had prior infections such as tuberculosis are at increased risk of pulmonary NTM disease. Subjects with advanced HIV infection (CD4<50) or immune-related genetic disorders (e.g., interferongamma deficiency or receptor deficiency, interleukin-12 deficiency) may develop pulmonary disease as part of a disseminated (e.g., widespread in the body) NTM infection. The subject to be treated may have any of the foregoing indications, e.g., in addition to a bacterial infection.

The methods compositions and methods described herein may be used to reduce a level of infection. For example, the methods may decrease a level of infection (e.g., number of bacteria or size of infection), as compared to a reference. For example, the infection may decrease by 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.

Pharmaceutical Compositions

The antibacterial agents described herein are preferably formulated into pharmaceutical compositions for administration to human subjects in a biologically compatible form suitable for administration in vivo.

The compositions described herein may be administered to a subject in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art. The compositions described herein may be administered, for example, by any route that allows the composition (e.g., an unencapsulated mixture of enzymes and/or a supramolecular structure, e.g., liposome, micelle, or LNP) to reach the target cells. The composition may be administered, for example, by oral, parenteral, intrathecal, intracerebroventricular, intraparenchymal, buccal, sublingual, nasal, rectal, patch, pump, ortransdermal administration and the pharmaceutical compositions formulated accordingly. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, intracerebroventricular, intraparenchymal, rectal, and topical modes of administration. In one embodiment, the composition is administered via aerosol. Parenteral administration may be by continuous infusion over a selected period of time. In some preferred embodiments, the compositions described herein are administered via inhalation. Administration of more than one antibacterial agent may be by the same route or by different routes and may occur sequentially or substantially simultaneously. For example, a first antibacterial agent of the combination may be administered by intravenous injection while a second therapeutic agent of the combination may be administered orally.

Certain compositions described herein may be administered, e.g., by inhalation. Inhalation may be oral inhalation or nasal inhalation. An inhalable composition described herein may be provided as a liquid dosage form or dry powder dosage form. A dry powder composition may be, e.g., administered by inhalation as is or after reconstitution in a vehicle (e.g., saline (e.g., isotonic saline), phosphate-buffered saline, or water).

Inhalable dry powder dosage forms may be prepared from liquid compositions described herein by drying (e.g., by freeze drying, spray drying, spray-freeze drying, or supercritical fluid technology). Inhalable dry powder dosage forms described herein may include a carrier (e.g., lactose, sucrose, mannitol, and the like), cryoprotectant (e.g., trehalose, mannitol, and the like), and/or antiadherent (e.g., glycine, L-leucine, serine, and the like). Inhalable dry powder dosage forms described herein may be administered using dry powder inhalers. Dry powder inhalers are known in the art and may or may not include a propellant. Non-limiting examples of dry powder inhalers can be found in Newman, Expert Opin. Biol. Ther., 4:23-33, 2004, the disclosure of which is incorporated herein by reference in its entirety.

Inhalable liquid dosage forms (e.g., aerosol formulations) described herein may be prepared using techniques and methods useful in the preparation of liquid compositions containing unencapsulated enzymes and/or supramolecular structures. Inhalable liquid dosage forms typically include a suspension of the enzymes and/or supramolecular structures described herein in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomizing device. Alternatively, the sealed container may be a unitary dispensing device, e.g., a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal after use. Where the dosage form contains an aerosol dispenser, it will contain a propellant, which can be a compressed gas, e.g., compressed air or an organic propellant, e.g., hydrofluoroalkane. The inhalable liquid dosage forms may be administered using a nebulizer. The process of pneumatically converting a bulk liquid into small droplets is called atomization. The operation of a pneumatic nebulizer requires a propellant as the driving force for liquid atomization. Various types of nebulizers are described in Respiratory Care, 45:609-622, 2000, the disclosure of which is incorporated herein by reference in its entirety. Alternatively, an inhalable liquid dosage form described herein may be administered using a metered-dose inhaler. Metered-dose inhalers are known in the art and typically include a canister, actuator, and a metering valve.

A composition described herein may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard- or soft-shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet. For oral therapeutic administration, a composition described herein may be incorporated with an excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, and wafers. A composition described herein may also be administered parenterally. A composition described herein may also be administered microneedle injection. Solutions of a composition described herein can be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, DMSO, and mixtures thereof with or without alcohol, and in oils. Under ordinary conditions of storage and use, these preparations may contain a preservative to prevent the growth of microorganisms. Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington’s Pharmaceutical Sciences (2012, 22nd ed.) and in The United States Pharmacopeia: The National Formulary (USP 41 NF 36), published in 2018. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that may be easily administered via syringe. Compositions suitable for buccal or sublingual administration include tablets, lozenges, and pastilles, where the active ingredient is formulated with a carrier, such as sugar, acacia, tragacanth, gelatin, and glycerin. Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base, such as cocoa butter.

In some embodiments, the compositions described herein are formulated with one or more excipients. For example, the composition (e.g., unencapsulated enzymes or a supramolecular structure, e.g., a liposome containing a cocktail of lytic enzymes) may be encapsulated and/or formulated in buffer, such as glycine, Tris, sodium citrate, sodium acetate, and MES, e.g., at a concentration of 10 mM to 200 mM, e.g., 50 mm to 150 mm, e.g., 10 mM, 20 mm, 30 mm, 40 mm, 50 mm, 60 mm, 70 mm, 80 mm, 90 mM, 100 mM, 110 mM, 120 mM, 130 mM, 140 mM, 150 mM, 160 mM, 170 mM, 180 mM, 190 mM, or 200 mM. The composition may be formulated at a pH of from 5 to 11 (e.g., a pH of 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, or 11). The composition may further include one or more excipients, such as CaCh, arginine, NaCI, sodium citrate, MgCh, or glycerol. In some embodiments, the composition includes, for example, 5 mM to 10 mM CaCh, 0 to 50 mM arginine, 0 to 200 mM NaCI, 0 to 1 mM sodium citrate, 0 to 1 mM MgCh, and/or 10-30% glycerol. In some embodiments, the composition includes 50 mM glycine, pH 8.5, 7.5 mM CaCh, 0.5 mM MgCh, 200 mM NaCI, 0.33 mM sodium citrate, and 10% glycerol. The formulation may further include TWEEN, e.g., TWEEN-80.

The composition described herein may be administered to an animal, e.g., a human, alone or in combination with pharmaceutically acceptable carriers, as noted herein, the proportion of which is determined by the solubility and chemical nature of the composition, chosen route of administration, and standard pharmaceutical practice.

The dosage of the compositions, e.g., a composition including a lytic protein, described herein, can vary depending on many factors, such as the pharmacodynamic properties of the antibacterial lytic proteins, the mode of administration, the age, health, and weight of the recipient, the nature and extent of the symptoms, the frequency of the treatment, and the type of concurrent treatment, if any, and the clearance rate of the composition in the animal to be treated. The compositions described herein may be administered initially in a suitable dosage that may be adjusted as required, depending on the clinical response. In some embodiments, the dosage of a composition, e.g., a composition including a lytic protein, is a prophylactically or a therapeutically effective amount. Furthermore, it is understood that all dosages may be continuously given or divided into dosages given per a given time frame. The composition can be administered, for example, every hour, day, week, month, or year. In some embodiments, the composition may be administered continuously or systemically.

Combination Therapies

The compositions described herein may be administered as part of a combination therapy. A combination therapy means that two (or more) different agents or treatments are administered to a subject as part of a defined treatment regimen for a particular disease or condition. For example, a first therapeutic agent may include a cocktail of unencapsulated proteins while a second therapeutic agent may include a supramolecular structure containing encapsulated proteins. The treatment regimen defines the doses and periodicity of administration of each agent such that the effects of the separate agents on the subject overlap. In some embodiments, the delivery of the two or more agents is simultaneous or concurrent and the agents may be co -formulated. In some embodiments, the two or more agents are not co-formulated and are administered in a sequential manner as part of a prescribed regimen. Sequential or substantially simultaneous administration of each therapeutic agent can be by any appropriate route including, but not limited to, oral routes, intravenous routes, intramuscular routes, and direct absorption through mucous membrane tissues. The therapeutic agents can be administered by the same route or by different routes. For example, a first therapeutic agent of the combination may be administered by intravenous injection or via aerosolization while a second therapeutic agent of the combination may be administered orally.

In some embodiments, the Lysin A, Lysin B, isoamylase, and/or a-amylase, e.g., in unencapsulated form, are administered together. Alternatively, the Lysin A, Lysin B, isoamylase, and/or a-amylase may be administered at different times.

In some embodiments, the Lysin A, Lysin B, isoamylase, and/or a-amylase, e.g., in unencapsulated form, e.g., having at least 85% sequence identity to a sequence of Table 1 , are administered together. Alternatively, the Lysin A, Lysin B, isoamylase, and/or a-amylase may be administered at different times.

In some embodiments, a first composition containing unencapsulated form of Lysin A, Lysin B, isoamylase, and/or a-amylase is administered as a combination therapy with a supramolecular structure (e.g., a liposome) containing one or more of a Lysin A, Lysin B, isoamylase, and/or a- amylase.

In any of the combination embodiments described herein, the first and second therapeutic agents may be administered simultaneously or sequentially, in either order. The first therapeutic agent (e.g., a composition containing unencapsulated proteins) may be administered immediately, up to 15 minutes, up to 30 minutes, up to 1 hour, up to 2 hours, up to 3 hours, up to 4 hours, up to 5 hours, up to 6 hours, up to 7 hours, up to, 8 hours, up to 9 hours, up to 10 hours, up to 11 hours, up to 12 hours, up to 13 hours, 14 hours, up to hours 16, up to 17 hours, up 18 hours, up to 19 hours up to 20 hours, up to 21 hours, up to 22 hours, up to 23 hours up to 24 hours or up to 1-7, 1-14, 1-21 or 1- 30 days before or after the second therapeutic agent (e.g., a supramolecular structure containing encapsulated proteins).

The pharmaceutical compositions described herein may further include an additional antibacterial agent that is administered in conjunction with the supramolecular structure that includes an antibacterial lytic protein.

The compositions and methods described herein may further include treatment for an underlying lung condition, e.g., that may be exacerbated by a bacterial infection, e.g., NTM infection. Suitable lung therapies include, without limitation, airway clearance, nebulizers, respirators, and inhalers, e.g., steroid inhalers.

Antibiotics

The additional antibacterial agent may be an antibiotic. Suitable antibiotics include, without limitation, penicillin G, penicillin V, methicillin, oxacillin, cioxacillin, dicloxacillin, nafcillin, ampicillin, amoxicillin, carbenicillin, ticarcillin, mezlocillin, piperacillin, azlocillin, temocillin, cepalothin, cephapirin, cephradine, cephaloridine, cefazolin, cefamandole, cefuroxime, cephalexin, cefprozil, cefaclor, loracarbef, cefoxitin, cefmatozole, cefotaxime, ceftizoxime, ceftriaxone, cefoperazone, ceftazidime, cefixime, cefpodoxime, ceftibuten, cefdinir, cefpirome, cefepime, chlorhexidine, BAL5788, BAL9141 , imipenem, ertapenem, meropenem, astreonam, clavulanate, sulbactam, tazobactam, streptomycin, neomycin, kanamycin, paromycin, gentamicin, tobramycin, amikacin, netilmicin, spectinomycin, sisomicin, dibekalin, isepamicin, tetracycline, chlortetracycline, demeclocycline, minocycline, oxytetracycline, methacycline, doxycycline, erythromycin, azithromycin, clarithromycin, telithromycin, ABT-773, lincomycin, clindamycin, vancomycin, oritavancin, dalbavancin, teicoplanin, quinupristin and dalfopristin, sulphanilamide, para-aminobenzoic acid, sulfadiazine, sulfisoxazole, sulfamethoxazole, sulfathalidine, linezolid, nalidixic acid, oxolinic acid, norfloxacin, perfloxacin, enoxacin, ofloxacin, ciprofloxacin, temafloxacin, lomefloxacin, fleroxacin, grepafloxacin, sparfloxacin, trovafloxacin, clinafloxacin, gatifloxacin, moxifloxacin, gemifloxacin, sitafloxacin, metronidazole, daptomycin, garenoxacin, ramoplanin, faropenem, polymyxin, tigecycline, AZD2563, trimethoprim, ethambutol, rifamycin, and rifampin. In some embodiments, multiple antibiotics are administered in combination with the compositions described herein. In some embodiments, the antibiotic is a cephalosporin, carbapenem (e.g., biapenem), penicillin, a macrolide, an aminoglycoside, or a fluoroquinolone. In some embodiments, the antibiotic is selected from the group consisting of thiacetazone, sq-109, bedaquiline, delamanid, pyrazinamide, and isoniazid.

In some embodiments, the antibiotic is a macrolide (e.g., azithromycin, clarithromycin, erythromycin). In some embodiments, the antibiotic is an aminoglycoside (e.g., kanamycin A, amikacin, tobramycin, dibekacin, gentamicin, sisomicin, netilmicin, neomycin (e.g., neomycin B, C, or E), streptomycin, or plazomicin).

Advantageously, in some embodiments, the synergy with the co-administered therapeutic agents may permit the antibiotic to be administered at a dose that would be subtherapeutic, if administered without the other therapeutic agents. The antibiotic may be formulated with the supramolecular structure containing the antibacterial lytic proteins. The antibiotic may be administered as a separate pharmaceutical composition. The antibiotic may be administered at a different time than the pharmaceutical composition containing the supramolecular structure with phage. In some preferred embodiments, the additional antibiotic is amikacin. The amikacin may be liposomal amikacin that is formulated, e.g., for inhalation.

Examples

The following examples are meant to illustrate the invention. They are not meant to limit the invention in any way.

Example 1. Treatment of M. abscessus infected macrophages

FIG. 1 is a graph showing serial dilutions of M. abscessus derived from infected macrophages that were treated with either free Lysin A, Lysin B, isoamylase, and a-amylase (ABIa) or liposomes containing ABIa for 24 hours. J774A.1 mouse macrophages were infected with Mycobacterium abscessus (MO 0:1). The length of growth after extraction from infected macrophages was 120 hours. A single dose was able to have greater than 100-fold effect relative to untreated cells.

Other Embodiments

All publications, patents, and patent applications mentioned in this specification are incorporated herein by reference in their entirety to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference in its entirety. Where a term in the present application is found to be defined differently in a document incorporated herein by reference, the definition provided herein is to serve as the definition for the term.

While the invention has been described in connection with specific embodiments thereof, it will be understood that invention is capable of further modifications and that this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure that come within known or customary practice within the art to which the invention pertains and may be applied to the essential features hereinbefore set forth, and follows in the scope of the claims.

Claims

1 . A composition comprising unencapsulated proteins, wherein the unencapsulated proteins comprise two or more of:

(a) a Lysin A;

(b) a Lysin B;

(c) an isoamylase; and

(d) an a-amylase.

2. The composition of claim 1 , wherein the unencapsulated proteins comprise:

(a) a Lysin A; and

(b) a Lysin B.

3. The composition of claim 1 , wherein the unencapsulated proteins comprise:

(a) a Lysin A; and

(b) an isoamylase.

4. The composition of claim 1 , wherein the unencapsulated proteins comprise:

(a) a Lysin A; and

(b) an a-amylase.

5. The composition of claim 1 , wherein the unencapsulated proteins comprise:

(a) a Lysin B; and

(b) an isoamylase.

6. The composition of claim 1 , wherein the unencapsulated proteins comprise:

(a) a Lysin B; and

(b) an a-amylase.

7. The composition of claim 1 , wherein the unencapsulated proteins comprise:

(a) an isoamylase; and

(b) an a-amylase.

8. The composition of claim 1 , wherein the unencapsulated proteins comprise three or more of:

(a) a Lysin A;

(b) a Lysin B;

(c) an isoamylase; and

(d) an a-amylase.

9. The composition of claim 8, wherein the unencapsulated proteins comprise: (a) a Lysin A; (b) a Lysin B; and

(c) an isoamylase.

10. The composition of claim 8, wherein the unencapsulated proteins comprise:

(a) a Lysin A;

(b) a Lysin B; and

(c) an a-amylase.

11 . The composition of claim 8, wherein the unencapsulated proteins comprise:

(a) a Lysin A;

(b) an isoamylase; and

(c) an a-amylase.

12. The composition of claim 8, wherein the unencapsulated proteins comprise:

(a) a Lysin B;

(b) an isoamylase; and

(c) an a-amylase.

13. The composition of claim 1 , wherein the unencapsulated proteins comprise all four of:

(a) a Lysin A;

(b) a Lysin B;

(c) an isoamylase; and

(d) an a-amylase.

14. The composition of claim 1 , wherein the unencapsulated proteins comprise two or more of:

(a) a Lysin A comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 1-182;

(b) a Lysin B comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 183-241 ;

(c) an isoamylase comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 242-392; and

(d) an a-amylase comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 393-445.

15. The composition of claim 14, wherein the unencapsulated proteins comprise two or more of:

(a) a Lysin A comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2;

(b) a Lysin B comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; (c) an isoamylase comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and

(d) an a-amylase comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 393-398.

16. The composition of claim 14, comprising:

(a) a Lysin A comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 1-182; and

(b) a Lysin B comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 183-241.

17. The composition of claim 16, comprising:

(a) a Lysin A comprising an amino acid sequence having at least 85% sequence identity to SEQ ID

NO: 1 or SEQ ID NO: 2; and

(b) a Lysin B comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184.

18. The composition of claim 14, comprising:

(b) an isoamylase comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 242-392.

19. The composition of claim 18, comprising:

(a) a Lysin A comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2; and

(b) an isoamylase comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243.

20. The composition of claim 14, comprising:

(b) an a-amylase comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 393-445.

21. The composition of claim 20, comprising:

(b) an a-amylase comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 393-398.

22. The composition of claim 14, comprising:

(a) a Lysin B comprising an amino acid sequence having at least 85% sequence identity to any one of

SEQ ID NOs: 183-241 ; and

23. The composition of claim 22, comprising:

(a) a Lysin B comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; and

24. The composition of claim 14, comprising:

SEQ ID NOs: 183-241 ; and

25. The composition of claim 24, comprising:

(a) a Lysin B comprising an amino acid sequence having at least 85% sequence identity to SEQ ID

NO: 183 or SEQ ID NO: 184; and

26. The composition of claim 14, comprising:

(a) an isoamylase comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 242-392; and

27. The composition of claim 26, comprising:

(a) an isoamylase comprising an amino acid sequence having at least 85% sequence identity to SEQ

ID NO: 242 or SEQ ID NO: 243; and

28. The composition of claim 1 , comprising three or more of:

(a) a Lysin A comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 1-182; (b) a Lysin B comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 183-241 ;

29. The composition of claim 28, comprising three or more of:

(b) a Lysin B comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184;

(c) an isoamylase comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and

30. The composition of claim 28, comprising:

(b) a Lysin B comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 183-241 ; and

(c) an isoamylase comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 242-392.

31. The composition of claim 30, comprising:

(b) a Lysin B comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; and

(c) an isoamylase comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243.

32. The composition of claim 28, comprising:

(c) an a-amylase comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 393-445.

33. The composition of claim 32, comprising:

(c) an a-amylase comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 393-398.

34. The composition of claim 28, comprising:

(b) an isoamylase comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 242-392; and

35. The composition of claim 34, comprising:

(b) an isoamylase comprising an amino acid sequence having at least 85% sequence identity to SEQ

ID NO: 242 or SEQ ID NO: 243; and

36. The composition of claim 28, comprising:

(a) a Lysin B comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 183-241 ;

37. The composition of claim 36, comprising:

(a) a Lysin B comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184;

ID NO: 242 or SEQ ID NO: 243; and

38. The composition of claim 1 , comprising all four of:

39. The composition of claim 38, comprising:

40. The composition of any one of claims 1 to 39, wherein:

(a) the Lysin A comprises an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 2;

(b) the Lysin B comprises an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184;

(c) the isoamylase comprises an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and/or

(d) the a-amylase comprises an amino acid sequence having at least 90%, 95%, 97%, or 99% sequence identity to any one of SEQ ID NOs: 393-398.

41 . The composition of claim 40, wherein:

(a) the Lysin A comprises the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2;

(b) the Lysin B comprises the amino acid sequence of SEQ ID NO: 183 or SEQ ID NO: 184;

(c) the isoamylase comprises the amino acid sequence of SEQ ID NO: 242 or SEQ ID NO: 243; and/or

(d) the a-amylase comprises the amino acid sequence of any one of SEQ ID NOs: 393-398.

42. The composition of any one of claims 1 to 41 , wherein the composition comprises a concentration of Lysin A, Lysin B, isoamylase, and/or a-amylase of from 0.1 mg/mL to 20 mg/mL.

43. The composition of claim 42, wherein the composition comprises a concentration of Lysin A, Lysin B, isoamylase, and/or a-amylase of from 1 mg/mL to 10 mg/mL.

44. A method of treating a bacterial infection comprising administering the composition of any one of claims 1 to 43 to the subject in an amount and for a duration sufficient to treat the bacterial infection.

45. The method of claim 44, wherein the bacterial infection is caused by an actinomycetia bacterium.

46. The method of claim 45, wherein the actinomycetia bacterium is a corynebacteriales or propionibacteriales bacterium.

47. The method of claim 46, wherein the corynebacteriales is a Mycobacterium species.

48. The method of claim 47, wherein the Mycobacterium species is M. tuberculosis, M. leprae, M. lepromatosis, M. avium, M. kansasii, M. fortuitum, M. chelonae, M. marinum, M. intracellulare, M. abscessus, M. chimera, M. boletti, M. fortuitum, M. goodii, or M. masiliense.

49. The method of claim 46, wherein the corynebacteriales is a Nocardia, Corynebacterium, or Rhodococcus.

50. The method of claim 49, wherein:

(a) the Nocardia species is N. brasiliensis, N. cyriacigeorgica, N. farcinica, N. nova, N. asteroids, N. brasiliensis, or N. caviae;

(b) the Corynebacterium species is C. glutamicum or C. diphtheriae or

(c) the Rhodococcus species is R. fascians or R. equi.

51. The method of claim 46, wherein the actinomycetia is a propionibacteriales.

52. The method of claim 51 , where the propionibacteriales is a Cutibacterium species.

53. The method of claim 52, wherein the Cutibacterium species is C. acnes.

54. The method of any one of claims 44 to 53, further comprising administering a supramolecular structure comprising two or more of:

(a) a Lysin A;

(b) a Lysin B;

(c) an isoamylase; and

(d) an a-amylase.

55. The method of claim 54, wherein the supramolecular structure comprises: (a) a Lysin A; and

(b) a Lysin B.

56. The method of claim 54, wherein the supramolecular structure comprises:

(a) a Lysin A; and

(b) an isoamylase.

57. The method of claim 54, wherein the supramolecular structure comprises:

(a) a Lysin A; and

(b) an a-amylase.

58. The method of claim 54, wherein the supramolecular structure comprises:

(a) a Lysin B; and

(b) an isoamylase.

59. The method of claim 54, wherein the supramolecular structure comprises:

(a) a Lysin B; and

(b) an a-amylase.

60. The method of claim 54, wherein the supramolecular structure comprises:

(a) an isoamylase; and

(b) an a-amylase.

61 . The method of claim 54, wherein the supramolecular structure comprises three or more of:

(a) a Lysin A;

(b) a Lysin B;

(c) an isoamylase; and

(d) an a-amylase.

62. The method of claim 61 , wherein the supramolecular structure comprises:

(a) a Lysin A;

(b) a Lysin B; and

(c) an isoamylase.

63. The method of claim 61 , wherein the supramolecular structure comprises:

(a) a Lysin A;

(b) a Lysin B; and

(c) an a-amylase.

64. The method of claim 61 , wherein the supramolecular structure comprises:

(a) a Lysin A;

(b) an isoamylase; and

(c) an a-amylase.

65. The method of claim 61 , wherein the supramolecular structure comprises:

(a) a Lysin B;

(b) an isoamylase; and

(c) an a-amylase.

66. The method of claim 54, wherein the supramolecular structure comprises all four of:

(a) a Lysin A;

(b) a Lysin B;

(c) an isoamylase; and

(d) an a-amylase.

67. The method of claim 54, wherein the supramolecular structure comprises two or more of:

68. The method of claim 67, wherein the supramolecular structure comprises two or more of:

69. The method of claim 67, wherein the supramolecular structure comprises:

(a) a Lysin A comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 1-182; and (b) a Lysin B comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 183-241.

70. The method of claim 69, wherein the supramolecular structure comprises:

71 . The method of claim 67, wherein the supramolecular structure comprises:

72. The method of claim 71 , wherein the supramolecular structure comprises:

73. The method of claim 67, wherein the supramolecular structure comprises:

74. The method of claim 73, wherein the supramolecular structure comprises:

75. The method of claim 67, wherein the supramolecular structure comprises:

(a) a Lysin B comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 183-241 ; and

76. The method of claim 75, wherein the supramolecular structure comprises:

77. The method of claim 67, wherein the supramolecular structure comprises:

78. The method of claim 77, wherein the supramolecular structure comprises:

79. The method of claim 67, wherein the supramolecular structure comprises:

80. The method of claim 79, wherein the supramolecular structure comprises:

(a) an isoamylase comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and

81 . The method of claim 54, wherein the supramolecular structure comprises three or more of:

82. The method of claim 81 , wherein the supramolecular structure comprises three or more of:

83. The method of claim 81 , wherein the supramolecular structure comprises:

84. The method of claim 83, wherein the supramolecular structure comprises:

85. The method of claim 81 , wherein the supramolecular structure comprises:

86. The method of claim 85, wherein the supramolecular structure comprises:

(b) a Lysin B comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 183 or SEQ ID NO: 184; and (c) an a-amylase comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 393-398.

87. The method of claim 81 , wherein the supramolecular structure comprises:

88. The method of claim 87, wherein the supramolecular structure comprises:

(b) an isoamylase comprising an amino acid sequence having at least 85% sequence identity to SEQ ID NO: 242 or SEQ ID NO: 243; and

89. The method of claim 81 , wherein the supramolecular structure comprises:

90. The method of claim 89, wherein the supramolecular structure comprises:

91 . The method of claim 54, wherein the supramolecular structure comprises all four of:

(b) a Lysin B comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 183-241 ; (c) an isoamylase comprising an amino acid sequence having at least 85% sequence identity to any one of SEQ ID NOs: 242-392; and

92. The method of claim 91 , wherein the supramolecular structure comprises:

93. The method of any one of claims 54 to 92, wherein the supramolecular structure comprises:

94. The method of claim 93, wherein the supramolecular structure comprises:

95. The method of any one of claims 54 to 94, wherein the supramolecular structure comprises a Z- average mean particle diameter of from 75 nm to 750 nm.

96. The method of claim 95, wherein the Z-average mean particle diameter is from 250 nm to 750 nm.

97. The method of claim 96, wherein the Z-average mean particle diameter is from 75 nm to 250 nm.

98. The method of any one of claims 54 to 97, wherein the supramolecular structure is a lipid nanoparticle.

99. The method of any one of claims 54 to 97, wherein the supramolecular structure is a micelle.

100. The method of any one of claims 54 to 97, wherein the supramolecular structure is a liposome.

101. The method of claim 100, wherein the liposome is unilamellar.

102. The method of claim 100, wherein the liposome is multilamellar.

103. The method of any one of claims 54 to 102, wherein the supramolecular structure comprises polydispersity index of from 0.05 to 0.3.

104. The method of any one of claims 54 to 103, wherein the supramolecular structure comprises one or more lipids.

105. The method of claim 104, wherein at least one of the one or more lipids is an ionizable lipid.

106. The method of claim 104 or 105, wherein the lipid comprises 1 ,2-dioleoyl-sn-glycero-3- phosphocholine (DOPC), 1 ,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), or 1 ,2-dioleoyl-sn- glycero-3-phospho-L-serine (DOPS).

107. The method of claim 105, wherein the lipid is a sterol.

108. The method of claim 107, wherein the sterol is cholesterol.

109. The method of any one of claims 104 to 108, wherein the supramolecular structure comprises a mixture of lipids.

110. The method of claim 109, wherein the mixture of lipids comprises DOPC, DOPE, DOPS, and cholesterol.

111. The method of claim 110, wherein the DOPC, DOPE, DOPS, and cholesterol are present at a molar ratio of from 1 -20:1-20:1-5:1-5.

112. The method of claim 111 , wherein the DOPC, DOPE, DOPS, and cholesterol are present at a molar ratio of from 10:10:3:4.

113. The method of any one of claims 54 to 112, wherein the supramolecular structure comprises a concentration of lipids of from 0.03 mg/mL to 10 mg/mL.

114. The method of claim 113, wherein the supramolecular structure comprises a concentration of lipids of from 1 mg/mL to 5 mg/mL.

115. The method of any one of claims 54 to 114, wherein the supramolecular structure comprises a targeting moiety.

116. The method of claim 115, wherein the targeting moiety is an extracellular targeting moiety targeting a professional antigen presenting cell.

117. The method of claim 116, wherein the professional antigen presenting cell is a macrophage or a dendritic cell.

118. The method of any one of claims 115 to 117, wherein the targeting moiety comprises phosphatidylserine.

119. The method of any one of claims 54 to 118, wherein the composition is administered prior to the supramolecular structure.

120. The method of any one of claims 54 to 118, wherein the composition is administered after the supramolecular structure.

121 . The method of any one of claims 54 to 118, wherein the composition is administered at substantially the same time as the supramolecular structure.

122. The method of any one of claims 44 to 121 , further comprising administering an antibiotic.

123. The method of claim 122, wherein the antibiotic is a cephalosporin, a carbapenem, a penicillin, an aminoglycoside, a cephalosporin, a rifamycin, a macrolide, or a fluoroquinolone.

124. The method of claim 122, wherein the antibiotic is thiacetazone, sq-109, bedaquiline, delamanid, pyrazinamide, or isoniazid.

125. The method of claim 122, wherein the antibiotic is azithromycin, clarithromycin, ethambutol, rifampin, biapenem, or amikacin.

126. The method of any one of claims 44 to 125, wherein the composition is administered intravenously, orally, or via inhalation.